GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2021

S

SENATE BILL 711

Judiciary Committee Substitute Adopted 7/1/21 Finance Committee Substitute Adopted 7/21/21 PROPOSED COMMITTEE SUBSTITUTE S711-PCS35328-BPx-20

	Short Title:	NC Compassionate Care Act.	(Public)	
	Sponsors:			
	Referred to:			
		April 8, 2021		
1		A BILL TO BE ENTITLED		
2	AN ACT ENA	CTING THE NORTH CAROLINA COMPASSIONATE CARE A	CT.	
3		ssembly of North Carolina enacts:		
4		CTION 1. Chapter 90 of the General Statutes is amended by adding	a new Article	
5	to read:			
6		"Article 5H.		
7		"North Carolina Compassionate Care Act.		
8	" <u>§ 90-113.110</u> .			
9		le shall be known and may be cited as the "North Carolina Compa	ssionate Care	
10	Act."	to shar be known and may be ched as the Tronth Caronna compe	bbiolitic Cure	
11		. Legislative findings and purpose.		
12		al Assembly makes the following findings:		
13	(1)		cannabinoid	
14	<u>(1)</u>	compounds are effective at alleviating pain, nausea, and oth		
15		associated with several debilitating medical conditions.	<u>er symptoms</u>	
16	(2)	•	ave removed	
17	<u>(2)</u>	state-level criminal penalties for the medical use, cultivation, ar		
18		of cannabis, and in enacting this Article, North Carolina now		
19		action to preserve and enhance the health and welfare of its citiz		
20	(3)	This Article is intended to make only those changes to existing N		
20	<u>(5)</u>	laws that are necessary to protect patients and their doctors from		
22		civil penalties and is not intended to change current civil and		
23		governing the use of cannabis for nonmedical purposes.	<u>erminar iaws</u>	
24	<u>(4)</u>	The General Assembly enacts this Article pursuant to its police	ower to enact	
25	<u>(+)</u>	legislation for the protection of the health of its citizens, as re-		
26		State in the Tenth Amendment of the United States Constitution		
27	" <u>§ 90-113.112</u> .		<u>1.</u>	
28		ring definitions apply in this Article:		
29	<u>(1)</u>	• • • • • • • • • • • • • • • • • • • •	olely from an	
30	<u>(1)</u>	intrastate source that is possessed by a qualified patient, o	•	
31		possessed by a qualified patient and the qualified patient		
32		caregiver, in an amount that does not exceed what is reasonably		
32 33		assure the uninterrupted availability of cannabis for a period of 3		
33 34		form recommended by the qualified patient's physician for the		
54		torm recommended by the quantied patient's physician for the	ic purpose of	



D

(General Assemb	oly Of North Carolina	Session 2021
1		alleviating the symptoms or effects of the	qualified patient's debilitating
2		medical condition.	
3	<u>(2)</u>	Advisory Board The Compassionate Use	Advisory Board established in
4		<u>G.S. 90-113.113.</u>	
5	<u>(3)</u>	Bona fide physician-patient relationship. – A	treatment relationship between
6		a physician and a patient in which the ph	•
7		assessment of the patient's medical history, in	
8		prescription history in the Controlled Subst	1 1 1
9		current medical condition, including an in-per	
0		the physician is available or offers to provide the	
11		the patient, including patient examinations, to	•
12		use of cannabis as a treatment for the patient's	
13	$\frac{(4)}{(5)}$	<u>Cannabis. – Marijuana as defined in G.S. 90-8</u>	
14	<u>(5)</u>	Cannabis-infused product. – A product infused	
15		for use or consumption other than by inhalation	
16		includes a tablet, a capsule, a concentrated	• •
17		suspension, a topical preparation, a transder	· · ·
18		preparation, a gelatinous cube, a gelatinous rec	
19	(\mathbf{C})	cube or rectangular cuboid shape, a resin, or a	
20 21	<u>(6)</u>	Commission. – The Medical Cannabis Product	tion Commission established in
22	(7)	<u>G.S. 90-113.117.</u> Debilitating medical condition A diagnosia	of one on more of the following
22	<u>(7)</u>	<u>Debilitating medical condition. – A diagnosis</u> for which a physician provides a written certif	
25 24			Ication:
24 25			
25 26			ciency virus (HIV)
20 27		c.Positive status for human immunodeficd.Acquired immune deficiency syndrom	•
28			<u>e (AIDS).</u>
29 29		<u>e.</u> <u>Amyotrophic lateral sclerosis (ALS).</u> <u>f.</u> <u>Crohn's disease.</u>	
30		<u>g.</u> <u>Sickle cell anemia.</u>	
31			
32		<u>h.</u> <u>Parkinson's disease.</u> <u>i.</u> <u>Post-traumatic stress disorder, subject</u>	t to evidence that an applicant
33		experienced one or more traumatic eve	1 I
34		include, but is not limited to, proof o	-
35		combat zone, that the person was the	
36		crime, or that the person was a first re	
37		shall not be required.	
38		j. <u>Multiple sclerosis.</u>	
39			
40		k.Cachexia or wasting syndrome.l.Severe or persistent nausea in a perso	on who is not pregnant that is
41		related to end-of-life or hospice ca	are, or who is bedridden or
42		homebound because of a condition.	
13		m. A terminal illness when the patient's re	emaining life expectancy is less
14		than six months.	• • •
15		n. A condition resulting in the individual	receiving hospice care.
16		o. Any other serious medical condition	
17			oard, as provided for in
18		<u>G.S. 90-113.113.</u>	
19	<u>(8)</u>	<u>Department. – The North Carolina Depart</u>	tment of Health and Human
		-	

Ge	eneral Assemb	ly Of North Carolina	Session 2021
1	<u>(9)</u>	Designated caregiver. – A person who possesses a valid	l registry identification
2		card issued by the Department authorizing the person	to assist a qualifying
3		patient with the medical use of cannabis. A designate	d caregiver shall be at
4		least 21 years of age unless the person is the parent or	legal guardian of each
5		qualifying patient the person assists.	
6	<u>(10)</u>	Medical cannabis center A facility owned and oper	ated by a supplier that
7		possesses and dispenses cannabis and cannabis-infuse	ed products to registry
8		identification cardholders for human consumption.	
9	<u>(11)</u>	Medical use of cannabis or medical use The acqui	
0		possession, preparation, transportation, or use	
1		cannabis-infused products, or paraphernalia used to	
2		products, to treat or alleviate a qualifying patient's	-
3		condition or symptoms associated with the qualifying	
4		medical condition and includes the transfer of cann	-
.5		designated caregiver to a qualifying patient whom the	
6		authorized to assist. "Medical use" does not include the	
17 18		from cannabis by solvent extraction other than water	•••••••
18 19		glycol, vegetable oil, or food grade ethanol (ethyl extraction is done by a processing facility.	alconol), unless the
20	(12)	Physician. – A person licensed under Article 1 of Cha	nter 90 of the General
21	(12)	Statutes who is in good standing to practice medicine i	-
22	(13)	Production facility. – A facility owned and operate	
23	<u>(15)</u>	cultivates, possesses, and produces cannabis and canna	• • •
24	(14)	Qualified patient. – A person who has been diagnos	- · · · · · · · · · · · · · · · · · · ·
25	<u>(11)</u>	having a debilitating medical condition and has	
26		certification.	
27	(15)	Registry identification card. – A document issued b	by the North Carolina
28	<u></u>	Department of Health and Human Services pursuant to	-
29		identifies a person as a qualified patient or a designated	l caregiver.
30	<u>(16)</u>	Registry identification cardholder A qualified pa	tient or a designated
31		caregiver who holds a valid registry identification car	d issued by the North
32		Carolina Department of Health and Human S	ervices pursuant to
3		<u>G.S. 90-113.115.</u>	
4	<u>(17)</u>	Regulated medical cannabis supply system or system	-
35		by the North Carolina Department of Health and Huma	
6		G.S. 90-113.119 to provide a safe method for produ	
37		cannabis and cannabis-infused products to registry ider	
8	<u>(18)</u>	Smoking. – The use or possession of a lighted cannabia	▲
89 10	<u>(19)</u>	Supplier. – A person licensed pursuant to G.S. 90-113.	
10		and cannabis-infused products as authorized by thi	
1		cultivates cannabis, owns and operates one or more me	
42 12		and owns and operates one or more production fac	cilities as set forth in
13	(20)	<u>G.S. 90-113.119.</u>	£1
14 15	<u>(20)</u>	<u>Usable cannabis. – The dried buds and mature female</u>	±
15 16		the genus Cannabis, and any mixture or preparat appropriate for medical use as provided in this Article.	
⊦o ⊦7	(21)	<u>Appropriate for medical use as provided in this Article.</u> Vaping. – The use of a product which heats a liquid or	
+7 8	<u>(21)</u>	<u>in a manner so as to release an aerosol.</u>	omer tortil of califiable
+8 9	(22)	<u>In a manner so as to release an aerosol.</u> Written certification. – A statement signed by a phy	cician with whom the
19 50	<u>(22)</u>	patient has a bona fide physician-patient relationship in	
0		patient has a bona nue physician-patient relationship in	ureating the following:

General Assem	bly Of	North Carolina	Session 2021
	<u>a.</u>	In the physician's professional opinion, the	ne patient has a debilitating
		medical condition.	-
	<u>b.</u>	The patient's debilitating medical condition	n.
	<u>c.</u>	In the physician's professional opinion, the	
	_	the medical use of cannabis would likely	
		the patient.	
	<u>d.</u>	The delivery method of the cannabis.	
	e.	The amount and dosage of the cannabis of	r cannabis-infused product.
		not to exceed an adequate supply.	<u> </u>
	<u>f.</u>	The period of time for which the written	certification is valid, not to
	_	exceed one year.	
§ 90-113.113.	Con	passionate Use Advisory Board; memb	ership; terms; meetings;
		xpenses.	
		oard Established. – The Compassionate Use A	dvisory Board is established
and shall consist	t of 13	members as follows:	-
(1)	The	Governor shall appoint members to the Advi	sory Board as follows:
	<u>a.</u>	A physician specializing in pain managem	•
	<u>b.</u>	A general physician.	
		A physician specializing in osteopathic m	edicine.
	<u>c.</u> <u>d.</u>	A physician who is board-certified to pra	ctice addiction medicine in
		North Carolina.	
	<u>e.</u>	A research scientist with expertise in	the field of cannabinoid
		medicine.	
	<u>f.</u>	A licensed pharmacist.	
	<u>g.</u>	A registry identification cardholder or,	for an appointment made
		before registry identification cards are	
		debilitating medical condition who intend	s to use cannabis.
	<u>h.</u>	A parent of a minor qualified patient or	, for an appointment made
		before registry identification cards are iss	sued, one parent of a minor
		with a debilitating medical condition who	intends to use cannabis.
	<u>i.</u>	A representative of a licensed supplier of	r, for an appointment made
		before suppliers are licensed, a prospectiv	e supplier.
<u>(2)</u>	Two	members appointed by the General Assemb	ly upon recommendation of
	the S	peaker of the House of Representatives in acc	cordance with G.S. 120-121.
<u>(3)</u>	Two	members appointed by the General Assemb	ly upon recommendation of
	the I	President Pro Tempore of the Senate in accord	dance with G.S. 120-121.
(b) Term	ns M	embers of the Advisory Board shall serve a	a four-year term, beginning
effective July 1	of the y	year of appointment, and may be reappointed	to a second four-year term.
(c) Chair	<u>r. – The</u>	e members of the Advisory Board shall elect a	chair. The chair shall serve
a two-year term	and ma	y be reelected.	
(d) Vaca	ncies	- Any appointment to fill a vacancy on the Ac	lvisory Board created by the
resignation, disn	nissal,	death, or disability of a member shall be mad	e by the original appointing
		or the balance of the unexpired term.	
(e) Meet	ings. –	The Advisory Board shall meet at least two ti	mes per year for the purpose
of reviewing pet	titions t	o add debilitating medical conditions.	
(f) Powe	er. – Tł	e Advisory Board shall have the power to ap	pprove adding a debilitating
nedical condition	on by a	majority vote of the members present and vo	<u>ting.</u>
		Seven members of the Advisory Board shall	constitute a quorum for the
transaction of bu			
		The members of the Advisory Board shall rec	
travel and subsis	stence e	expenses in accordance with the provisions of	FG S 138-5

	General Assem	bly Of North Carolina	Session 2021
1	"8 90-113.114.	Physician requirements.	
2		ired Education. – Before providing a written certification	n to a qualified patient.
3		complete a three-hour continuing medical education cou	· ·
4		supplemental medical education course thereafter, as a	
5		al Board. Records documenting compliance must b	
6		s and may be inspected by the Department or by the N	
7	Board or its ager	• • • • •	
8	(b) Regis	stration of Written Certification. – A physician sha	all register a written
9	certification for	a qualified patient in the medical cannabis registry dat	-
10		ied by the Department.	
11		<u>aluation. – A physician shall reevaluate an existing qual</u>	•
12		efficacy of the use of cannabis as a treatment for the patie	
13		e per year, to include an in-person physical examinatio	
14		tion history in the Controlled Substances Reporting Syst	
15		to Update A physician shall update the medical can	
16		ys after any change is made to the original written certin	fication to reflect such
17		g deactivation of a written certification.	
18		ation Requirement. – A physician shall provide educatio	i i i
19		ymptoms of cannabis use disorder and cannabis-induced	<u>psychosis upon initial</u>
20		ion and at least annually thereafter.	1.6.1
21		ictions. – A physician who provides written certification	
22		oyed by or have any direct or indirect economic interest in	
23 24		y. A physician may not evaluate patients or advertise of	n the site of a medical
24 25	cannabis center. 90-113.115.	Registry identification cards for qualified patie	onto and designated
23 26		ivers.	ents and designated
20 27		ications, Issuance, and Expiration of Registry Identif	fication Cards – The
28		l issue or renew a registry identification card to the follow	
20 29	(1)	Any individual who applies to the Department on fo	
30		Department demonstrating that the individual is a qu	.
31		debilitating medical condition for which a physician	
32		certification.	
33	<u>(2)</u>	Any individual who is at least 21 years of age who has	as (i) been named as a
34	<u>*</u>	designated caregiver in a registry identification card ap	
35		a qualified patient and (ii) agreed to serve as that qualified	•
36		caregiver. The Department may issue a registry id	
37		maximum of two designated caregivers named in	
38		approved application.	• •
39	The Departm	nent shall issue a registry identification card to an applic	ant within 14 business
40	days after approv	ving an application or renewal. The initial or renewal regi	stry identification card
41	expires one year	after the date of issuance.	
42	<u>(b)</u> Quali	fied Patients Under Age 18 The Department may not is	ssue or renew a registry
43	identification can	d to a qualified patient under 18 years of age unless each of	of the following criteria
44	<u>is met:</u>		
45	<u>(1)</u>	The qualified patient's physician has explained the pote	
46		of the medical use of cannabis to the qualified part	
47		guardian, or person having legal custody of the qualified	•
48	<u>(2)</u>	The qualified patient's physician restricts the qual	-
49		cannabis to a noninhalation consumption method, an	
50		and the qualified patient's designated caregivers agree	e to comply with this
51		restriction.	

	General Assemb	oly Of North Carolina	Session 2021
1	<u>(3)</u>	A parent, guardian, or person having legal custody	y of the qualified patient
2		consents in writing to (i) allow the qualified patient's	s medical use of cannabis,
3		(ii) serve as one of the qualified patient's designation	ated caregivers, and (iii)
		control the acquisition of the cannabis, the dosage,	and the frequency of the
		medical use of cannabis by the qualified patient.	
		w of Applications. – The Department shall verify the	
		cation card application or renewal application submitte	-
	* *	e or deny an application or renewal application within ils and Appeals. – The Department may deny a re	• •
		newal application only if the applicant fails to provide	
		section or if the Department determines that the	
	-	ains false information. Denials may be appealed by	* *
		rticle 3 of Chapter 150B of the General Statutes. Arti	
	the General Stat	utes governs judicial review of an administrative d	lecision made under this
	section.		
	(e) <u>Regis</u>	try Identification Card Information Each registry	identification card issued
	by the Departme	nt shall be printed with tamper-resistant technology an	nd shall contain at least all
	of the following	information:	
	<u>(1)</u>	The name of the cardholder.	
	<u>(2)</u>	The address of the cardholder.	
	<u>(3)</u>	The cardholder's date of birth.	
	<u>(4)</u>	A designation of whether the cardholder is a	designated caregiver or
		qualifying patient.	
	<u>(5)</u>	The date of issuance and expiration date of the regis	
	<u>(6)</u>	A random alphanumeric identification number that is	
	<u>(7)</u>	If the cardholder is a designated caregiver, th	-
		identification number of the qualifying patients that	t the designated caregiver
	$\langle 0 \rangle$	is authorized to assist.	
	$\frac{(8)}{(9)}$	A photograph of the cardholder.	
	(f) $\frac{(9)}{N_0 + if}$	<u>The delivery method of the cannabis.</u> ication of Changes. – Individuals issued registry ident	fightion conde and subject
	(f) Notified to all of the follo		incation cards are subject
	<u>(1)</u>	A qualified patient who has been issued a registry	videntification card shall
	<u>(1)</u>	notify the Department of any change in the qualifier	
		or designated caregiver and submit a fifty dol	
		Department within 15 days after the change occurs	
		fails to notify the Department of any of these char	· ·
		time frame commits an infraction and is subject to	
		hundred dollars (\$100.00).	<u> </u>
	<u>(2)</u>	A designated caregiver shall notify the Department	of any change in name or
		address and submit a fifty dollar (\$50.00) fee to the	
		days after the change occurs. A designated caregiv	
		Department of any of these changes within the spec	
		an infraction and is subject to a fine not to exc	eed one hundred dollars
		<u>(\$100.00).</u>	
	<u>(3)</u>	When a qualified patient or designated caregiver n	
		any change, as required by this subsection, the D	-
		qualified patient and each designated caregiver a n	
		card within 10 days after receiving the updated inform	mation and the fifty dollar
)		<u>(\$50.00) fee.</u>	

General Assem	oly Of North Carolina	Session 2021
<u>(4)</u>	When a qualified patient who possesses a registry identi	ification card notifies
	the Department of a change in designated caregiver, t	he Department shall
	notify the designated caregiver of record of the change	-
	receiving notification of the change. The protections	
	Article to the designated caregiver of record shall exp	
	designated caregiver of record is notified by the Department	
	designated caregiver.	
(5)	If a qualified patient or a designated caregiver loses a r	registry identification
	card, the cardholder shall notify the Department within	
	the card. The notification shall include a fifty dollar (\$50	
	for a new card. Within five days after receiving notifica	
	identification card, the Department shall issue the cardl	
	identification card with a new random identification num	
(g) Suspe	ensions or Revocations. – If the Department determines the	
	regiver has violated any provision of this Article, the Depa	
	lified patient's or designated caregiver's registry identification	
•	ay be appealed by filing a contested case petition under	-
150B of the Gen	• • • • •	
	. – The North Carolina Medical Care Commission	shall adopt rules to
	ovisions of this section. The rules shall establish requirem	
	fication cards to qualified patients and designated caregiver	
at least all of the	· · · · ·	<u>s, which shall morade</u>
<u>(1)</u>	The method of demonstrating written certification	on as defined in
<u>(1)</u>	G.S. 90-113.112.	on, us defined in
(2)	The amount of the initial or renewal application fee, where the init	hich shall not exceed
<u>\</u>	fifty dollars (\$50.00) per application or renewal applicat	
(3)	The name, address, and date of birth of the qualified pat	
$\frac{(3)}{(4)}$	The name, address, and telephone number of the qualifie	
$\frac{(1)}{(5)}$	The name, address, and date of birth of each of the	· · ·
<u>(57</u>	designated caregivers, if any.	e quannea patient s
<u>(6)</u>	<u>A limitation on the number of written certifications a pl</u>	hysician may issue at
<u>(0)</u>	any given time.	rysteran may issue at
"8 90-113 116	Requirement to carry and disclose registry identifi	ication card to law
	cement.	cution cutie to lus
	irement to Carry. – A registry identification cardholder sh	all carry the registry
	rd together with valid identification whenever the re	
	rying cannabis or cannabis-infused product as provided in	
	irement to Disclose. – The registry identification cardholde	
	t officer that the registry identification cardholder ho	
	d when approached or addressed by the officer and shall dis	
	d and valid identification at the request of a law enforcem	<u></u>
	Confidential Medical Cannabis Registry Database.	ent officer.
	dential Medical Cannabis Registry Database. – The Depa	ortmant shall create a
	tial, electronic medical cannabis registry database of all c	
	ivers to whom the Department has issued registry identical	• •
	ncies may contact the Department to confirm registry ident shall monitor the medical cannabis registry database and	
-		
-	s patterns of written certifications that are unusual, the Dep	
	heral's Office of its findings. The Office of the Attorney Ge	
Departments fin	dings to determine if the findings should be reported to	me state Dureau OI

General Assemb	oly Of North Carolina	Session 2021	
Investigation and	the appropriate sheriff for investigation of possible violations	of State or federal	
	e shall consist of at least the following information:	or blace of reactai	
	(1) The name and address of the registry identification cardholder.		
$\frac{(1)}{(2)}$	The name, address, and hospital affiliation of the physicia		
<u>(2)</u>	written certification of the qualified patient's debilitating co		
(3)	A photograph of the registry identification cardholder.	<u>indition.</u>	
	dential Nature of Information Collected by Department. –	Applications and	
	nation submitted by qualified patients, including information	* *	
	vers and physicians, individual names, and other identifying i		
	registry database, are confidential, exempt from the provision		
	atutes, and are not subject to disclosure, except to authorized		
	ecessary to perform official duties of the Department and	· ·	
•	red in subsection (h) of this section.		
	ty for Confidentiality Breaches. – Any person, including an em	nlovee or official	
	t or another State agency or local government, who breaches t		
	btained pursuant to this section is guilty of a Class 2 misder		
	for a violation under this subsection shall not exceed one		
<u>(\$1,000).</u>	i for a violation under this subsection shall not exceed one	ulousallu uollais	
	ts of Falsified or Fraudulent Application Information to I	aw Enforcement	
	hing in this section shall be construed to prevent Department	· · · · · · · · · · · · · · · · · · ·	
	Forcement personnel about falsified or fraudulent information		
	by individual in support of an application for a registry identif		
	Medical Cannabis Production Commission.	<u>reation card.</u>	
	nission Established. – The Medical Cannabis Production	Commission is	
	hall consist of 11 members as follows:		
<u>(1)</u>	The Governor shall appoint members to the Medical Can	nabis Production	
<u>\</u>	Commission as follows:		
	<u>a.</u> <u>A qualified patient representative.</u>		
	b. Two industry representatives, subject to the limitati	ion that, although	
	the industry representatives may participate in a		
	process of adopting rules, the industry represen		
	participate in the license selection process	· · · · · · · · · · · · · · · · · · ·	
	representatives have applied for or have an affiliation		
	cannabis supplier license applicant through family o		
<u>(2)</u>	The Secretary of the Department, or designee.		
(3)	The Director of the North Carolina State Bureau of Investiga	ation, or designee.	
<u>(4)</u>	The Agriculture Commissioner, or designee.		
(5)	A sheriff designated by the North Carolina Sheriffs' Associa	ation.	
(6)	A chief of police designated by the North Carolina Associa		
	Police.		
<u>(7)</u>	A physician member of the North Carolina Medical Board	designated by the	
<u> </u>	North Carolina Medical Board.	<u>, </u>	
<u>(8)</u>	A member appointed by the General Assembly upon recom	mendation of the	
	Speaker of the House of Representatives in accordance with		
<u>(9)</u>	A member appointed by the General Assembly upon recom		
	President Pro Tempore of the Senate in accordance with G.S.	S. 120-121.	
(b) Terms	s Members of the Commission shall serve terms of four		
	f the year of appointment, and may be reappointed to a second		
	mbers designated by subdivisions (a)(1), (a)(2), and (a)(4) of		
	of any year evenly divisible by four. The terms of the remaini		
expire on June 30) of any year that follows by two years a year evenly divisible	by four.	

General Assembly Of North Carolina	Session 2021
(c) Chair. – The members of the Commission shall elect a chair. T	The chair shall serve a
two-year term and may be reelected.	
(d) Vacancies. – Any appointment to fill a vacancy on the Comm	nission created by the
resignation, dismissal, death, or disability of a member shall be made by the	•
authority and shall be for the balance of the unexpired term.	
(e) <u>Removal. – The appointing authority shall have the power to re</u>	emove any member of
the Commission appointed by that authority from office for misfeasa	-
nonfeasance.	1. 1
(f) <u>Expenses. – The members of the Commission shall receive pe</u>	
travel and subsistence expenses in accordance with the provisions of G.S.	
(g) Quorum. – Five members of the Commission shall constitu	ite a quorum for the
transaction of business.	
(h) Licensing Power. – The Commission shall have the power to ap	
medical cannabis supplier licenses upon recommendation of the Departme	
of the members present and voting. The Department shall evaluate the appli	
with G.S. 90-113.120 and submit a list of 20 recommended applicants to	
Commission shall approve 10 licenses from the list by a majority vote of	
and voting. In awarding the licenses, the Commission shall require each sup	
no more than four medical cannabis centers. Of the medical cannabis cen	iters operated by each
supplier, at least two shall be located in Tier 1 counties.	
(i) <u>License Suspension or Revocation. – The Commission may</u>	÷
medical cannabis supplier license if the Commission determines that t	* *
substantial compliance with this Chapter or with rules adopted by the	
subsection (k) of this section. The Department shall notify a supplier at lea	
of a proposed suspension or revocation, including the reasons for the susp	_
and any possible remedial options available to the supplier. The Commis	-
administer oaths and issue subpoenas to require the presence of persons a	-
papers, books, and records necessary to conduct a suspension or reve	
suspension or revocation may be appealed by filing a contested case petitic	ion under Article 3 of
<u>Chapter 150B of the General Statutes.</u>	Commission shall be
(j) <u>All administrative support and other services required by the</u> provided by the Department.	Commission shan de
(k) Rules. – The Commission, in consultation with the North Ca	arolina Madical Cara
Commission, shall adopt rules to implement the provisions of this section	
90-113.120, 90-113.121, and 90-113.122. The rules shall do all of the follo	
(1) Establish qualifications and requirements for licensure	
production of cannabis by a supplier, and for the proper	
cannabis centers and production facilities operated by s	-
(2) Ensure the equitable distribution of medical cannabis c	
State in order for registry identification cardholders to	
supply of cannabis and cannabis-infused products,	
overconcentration of medical cannabis centers in any or	
· · · · · · · · · · · · · · · · · · ·	
(3) <u>Establish civil penalties for minor violations of the</u> Chapter and rules adopted under the authority provided	-
"§ 90-113.119. Regulated medical cannabis supply system.	III uns subsection.
(a) Medical Cannabis Supply System. – The Medical Cannabis Pro-	oduction Commission
established in G.S. 90-113.118 shall establish a medical cannabis supply s	
suppliers to produce cannabis and cannabis-infused products in license	•
facilities and distribute them through medical cannabis centers. In esta	-
cannabis supply system, the Commission shall (i) provide a safe, regulate	-
appropriate for medical use by qualified registry identification cardle	
appropriate for medical use by quanned registry identification calu	ionacio issued unuel

General Assembly Of North Carolina Session 2021 1 G.S. 90-113.115, (ii) ensure statewide access to safe and affordable cannabis to registry 2 identification cardholders, (iii) establish a system that is well-regulated, includes a seed-to-sale tracking system, and is financially viable for suppliers to ensure the highest quality cannabis and 3 4 cannabis-infused products for patients, and (iv) generate sufficient revenue for the Commission 5 to oversee and for the Department to maintain and operate the system. 6 (b) Funding. – The General Assembly may appropriate funds for the initial development 7 and implementation of the medical cannabis supply system, but neither the Department nor the 8 Commission shall use any appropriations from the General Fund to operate the system. The intent 9 of the General Assembly is that the system shall be funded solely by the fees authorized in this 10 Article. 11 "§ 90-113.120. Medical cannabis supplier license. Definitions. – The following definitions apply in this section: 12 (a) Nonresident business. - An entity that has not been required to file an income 13 (1) 14 or franchise tax return with the State for three years prior to filing an initial 15 application for a medical cannabis supplier license that meets one or more of the following conditions: 16 17 Is a nonresident entity. a. Is a nonresident individual who owns an unincorporated business as a 18 <u>b.</u> 19 sole proprietor. 20 (2) Nonresident entity. – Defined in G.S. 105-163.1. 21 (3) Nonresident individual. – Defined in G.S. 105-153.3. 22 Prohibitions. – No person shall do any of the following without first obtaining a (b) medical cannabis supplier license from the Commission: 23 24 (1) Grow, cultivate, produce, or sell cannabis or cannabis-infused products. 25 Operate a business to produce cannabis or cannabis-infused products. (2)26 (3) Establish or operate a medical cannabis center for the sale of cannabis, 27 cannabis-infused products, and paraphernalia relating to the administration of 28 cannabis to qualified patients and designated caregivers who hold valid 29 registry identification cards. 30 Medical Cannabis Supplier License Application; Fees. – An applicant for a license (c) 31 under this subsection shall submit the required information on application forms provided by the 32 Department. The application form shall require at least all of the following: 33 The applicant's name and any legal names the applicant will use for facilities (1)34 where the applicant will produce cannabis and for each medical cannabis 35 center and production facility the applicant proposes to operate. 36 The address of each property, location, or premises the applicant will use to (2) 37 produce cannabis, of each production facility the applicant will use to process cannabis or produce cannabis-infused products, and of each medical cannabis 38 39 center the applicant will use to dispense or distribute cannabis. 40 Documentation demonstrating that the applicant possesses: (3) 41 Requisite expertise in controlled environment agriculture and at least <u>a.</u> 42 five years of experience in cultivation, production, extraction, product 43 development, quality control, and inventory management of medical cannabis in a state-licensed medical or adult use cannabis operation 44 45 meeting standards that the Commission shall specify by rule. 46 Significant technical and technological ability to cultivate, produce, b. 47 and distribute medical cannabis in a manner that meets industry 48 standards for production consistency and safe handling. 49 Relevant experience in securing cannabis production, testing, <u>c.</u> 50 resources, transportation, and personnel to operate as a safe and secure

	General Assemb	ly Of North Carolina	Session 2021
1		supplier in compliance with all state reg	ulations in which the applicant
2		has prior experience.	
3	<u>(4)</u>	Proposed operating procedures for each produc	
4		center, and component of the applicant's property	osed medical cannabis supply
5		system, including record keeping and se	curity requirements as the
6		Commission shall specify by rule.	
7	<u>(5)</u>	The name, address, and date of birth of each	n principal officer and board
8		member of the supplier.	
9	<u>(6)</u>	The name, address, and date of birth of each en	nployee of the supplier.
10	<u>(7)</u>	For first-year suppliers, a nonrefundable licen	se fee in the amount of fifty
11		thousand dollars (\$50,000) plus five thousand	nd dollars (\$5,000) for each
12		production facility or medical cannabis cent	er the applicant proposes to
13		operate under the license.	
14	<u>(8)</u>	For suppliers seeking license renewal, a non	refundable renewal fee in an
15		amount not less than ten thousand dollars (\$10,0	
16		(\$1,000) for each production facility or medica	al cannabis center the supplier
17		operates under the license as specified in rules	s adopted by the Commission
18		pursuant to G.S. 90-113.118 and annual audite	± •
19		by an independent certified public accountant.	
20	<u>(9)</u>	Proof the applicant has been a State resident for	r at least two years and will be
21		the majority owner of each medical cannabis	-
22		the applicant proposes to operate. The applic	cant may include nonresident
23		partners with demonstrated ownership and	operation experience in the
24		cultivation, production, extraction, product dev	
25		inventory management of cannabis products i	n a state-licensed medical or
26		adult use cannabis operation and shall provide p	proof of state residency for any
27		nonresident partner of the applicant.	
28	<u>(10)</u>	The name, address, and date of birth of any ind	ividual owning more than five
29		percent (5%) of the medical cannabis center	r and production facility the
30		supplier operates.	
31	<u>(11)</u>	Proof in a manner and amount as the Commis	sion shall specify by rule that
32		the applicant has sufficient liquid and nonliquid	assets to operate as a supplier
33		for two years as a part of the medical cannabis	supply system established by
34		this Article.	
35	<u>(12)</u>	Any other information the Department con	nsiders necessary to ensure
36		compliance with the terms of this Article.	
37		on. – Unless suspended or revoked, a medical car	nnabis supplier license is valid
38		exceed 12 months from the date of issuance.	
39		val. – A supplier shall apply for renewal, as nece	ssary, at least 30 days prior to
40	the expiration of a		
41		Frame for Issuance; Fees. – No later than 30 da	
42		subsection, the Department shall issue a supplier	• •
43		l employee listed on the application or renewa	I form upon receipt of a two
44		ar (\$250.00) fee per cardholder.	
45		cation of Changes. – An applicant or supplier s	
46		e information submitted on the license application	on or renewal form within 30
47 19	days after the cha		annahia aantan anaratad ha
48 40		bility of Records. – The records of a medical of a medical of the same restrictions imposed on phenomenon and the same restrictions imposed on phenomenon and the same restrictions imposed on phenomenon and the same restriction of the same restric	.
49 50		ject to the same restrictions imposed on ph .S. 90-85.36 applies to each medical cannabis co	•
50 51		Article 4A of Chapter 90 of the General Statutes.	emer as in it were a pharmacy
51	regulated ulluel P	ancie 4A of Chapter 30 of the Ocheral Statutes.	

General Assembly Of North Carolina

1	(i) Cannabis Production Site Card. – The Department shall issue a cannabis production
2	site card to each supplier for each production facility approved under this section. The card shall
3	be posted conspicuously at each production facility.
4	(j) Performance Requirements. – A supplier must begin cultivation of cannabis within
5	120 days of receiving a medical cannabis supplier license and begin selling cannabis and
6	cannabis-infused products in medical cannabis centers within 180 days of initiating cultivation.
7	(k) Criminal History Record Check. – In order to ensure compliance with this section,
8	the Department shall conduct a criminal history record check of any person whose name is
9	submitted on an application as an owner, director, or an employee of the supplier. When
10	requested by the Department, the North Carolina Department of Public Safety may provide to
11	the Department a person's criminal history from the State Repository of Criminal Histories. Such
12	requests shall not be due to a person's age, sex, race, color, national origin, religion, creed,
13	political affiliation, or handicapping condition as defined in G.S. 168A-3. For requests for a State
14	criminal history record check only, the Department shall provide to the Department of Public
15	Safety a form consenting to the check signed by the person to be checked and any additional
16	information required by the Department of Public Safety. National criminal record checks are
17	authorized for applicants who have not resided in the State of North Carolina during the past five
18	years. For national checks, the Department shall provide to the North Carolina Department of
19	Public Safety the fingerprints of the person to be checked, any additional information required
20	by the Department of Public Safety, and a form signed by the person to be checked consenting
21	to the check of the criminal record and to the use of fingerprints and other identifying information
22	required by the State or National Repositories. The fingerprints of the individual shall be
23	forwarded to the State Bureau of Investigation for a search of the State criminal history record
24	file, and the State Bureau of Investigation shall forward a set of fingerprints to the Federal Bureau
25	of Investigation for a national criminal history record check. The Department of Health and
26	Human Services shall keep all information pursuant to this section confidential. The Department
27	of Public Safety shall charge a reasonable fee for conducting the checks of the criminal history
28	records authorized by this section. All releases of criminal history information to the Department
29	shall be subject to, and in compliance with, rules governing the dissemination of criminal history
30	record checks as adopted by the North Carolina Department of Public Safety. All of the
31	information either department receives through the checking of the criminal history is privileged
32	information and for the exclusive use of that department.
33	(<i>l</i>) Duty to Update. – In order to continue to hold a license under this Article, a supplier
34	shall notify the Commission of any change in criminal history of any person required to be
35	evaluated by the Department under this section. The Commission may reevaluate the supplier's
36	eligibility for a license based on the notification and may modify or revoke the license or require
37	issuance of a new license with appropriate terms to exclude disqualifying persons.
38	(m) Disqualifications for Licensure The Commission shall not issue a license
39	authorized by this section to any of the following persons:
40	(1) <u>A person who has not paid the appropriate license or license renewal fee.</u>
41	(2) <u>An individual who is less than 21 years of age.</u>
42	(3) <u>A person who has served a sentence for any of the following felonies in the</u>
43	five years immediately preceding the date of license application: any Class A
44	through E felony; any felony that includes assault as an essential element of
45	the offense; any felony under Article 14 (Burglary and Other Housebreakings)
46	of Chapter 14 of the General Statutes; any felony under Article 16 (Larceny),
47	Article 16A (Organized Retail Theft), Article 17 (Robbery), Article 18
48	(Embezzlement), Article 19 (False Pretenses and Cheats), Article 19A
49	(Obtaining Property or Services by False or Fraudulent Use of Credit Device
50	or Other Means), Article 19B (Financial Transaction Card Crime Act), or
51	Article 19C (Financial Identity Theft) of Chapter 14 of the General Statutes.

General Assem	oly Of North Carolina	Session 2021
(4)	A person (or, with respect to a person who i	s not an individual, an owner.
<u></u>	director, or employee of the person) who at an	
	felony violation for manufacturing, selling, of	
	intent to manufacture, sell, deliver, or possess	
	substance, in violation of G.S. 90-95(b)(1).	s a Schedule 1 of 11 controlled
<u>(5)</u>	Except as otherwise provided in this subdivisi	ion a person who has not been
<u>(5)</u>	a resident of North Carolina for at least two	-
	license application, unless that person is a min	• 1
	who is the majority owner of the applicant. W	• •
	not an individual, a person that is a nonresiden	
(n) Admi	nistrative and Judicial Review. – Articles 3 a	
	govern administrative and judicial review of ar	-
nder this section	•	r administrative decision made
	<u>n.</u> Restrictions on supplier sales and supply.	
	ictions on Sales and Supply. – A person licensed	as a supplier under this Article
	following sales and supply restrictions:	as a supplier under uns Article
<u>(1)</u>	<u>The supplier may sell cannabis and cannabis-</u>	infused products only through
<u>(1)</u>	the medical cannabis center that the supplier is	
	section. A medical cannabis center shall not s	-
	products, or paraphernalia relating to the adm	
	person other than a qualified patient, desig	
	provided in subdivision (3) of this subsection.	• •
	not sell cannabis or cannabis-infused products	
	adequate supply to any qualified patient or des	
(2)	The supplier may sell only cannabis grown by	
<u>(2)</u>	facilities approved under this section. Except a	
	this subsection, the supplier shall not sell cann	-
	seeds, or cultivation equipment to any other	-
	medical cannabis center that the supplier is lice	· · · · · ·
(b) Resal	e. – The supplier may sell cannabis or cannabis	
nother licensed		
	Supplier reporting; monthly fees.	
	erly Reports. – Each supplier licensed under this	s Article shall submit quarterly
	partment on all financial transactions, including,	· ·
*	uses of cannabis and cannabis-infused products,	-
	products for no consideration with respect to early	
	ty operated by the supplier.	
	hly Fee. – Each supplier licensed under this section	ion shall pay to the Department
	ual to ten percent (10%) of the gross revenue de	1 1 1
	used products at all medical cannabis centers ope	
	truction. – Nothing in this section shall be constru	
	n from the reporting or remittance of sales tax fo	
sales tax may be		
	Exemption from criminal laws.	
	ption from Criminal Laws. – A supplier is exemp	ot from the criminal laws of this
	ion, production, delivery, or transportation of c	
	possession, production, delivery, or transportation of the	
	in which possession, production, delivery, or the	
	dividual is in compliance with this Article and ru	-
	of Exemption from Criminal Laws. – A person v	÷
	giver but who is otherwise authorized to possess	

	General Assem	bly Of North Carolina	Session 2021
1	cannabis for med	lical use pursuant to this Article ceases to be exempt as prov	vided in subsection
2		1 upon committing any of the following acts:	
3	<u>(1)</u>	Driving while impaired in violation of G.S. 20-138.1, 20-1	38.2. or 20-138.5.
4	(2)	Delivering cannabis to any individual who the person know	
5	<u>_/</u>	know is not a qualified patient or designated caregiver	
6		registry identification card issued under G.S. 90-113.115,	
7		holds a license under G.S. 90-120.	
8	<u>(3)</u>	Manufacturing or distributing cannabis at an address not	registered with the
9	<u>(0)</u>	Department.	
10	(4)	Failing to report transfer of cannabis authorized under	this Article to the
11		Department.	
12	"§ 90-113.124.]	Protections for the medical use of cannabis.	
13		gistry identification cardholder shall not be subject to arre	st, prosecution, or
14		anner for the possession or purchase of cannabis for medical u	
15		antity of usable cannabis possessed or purchased does not e	
16		nined by the qualified patient's physician.	<u> </u>
17		ble cannabis is infused or added as an ingredient to an edible	e cannabis product,
18	salve, tincture, or	r any other preparation to be consumed or used by a qualified	patient, the weight
19	of the other ing	redients that are not usable cannabis shall not be included	for the purpose of
20	determining whe	ther a qualified patient is in possession of an amount of can	nabis that exceeds
21	the qualified pati	ent's adequate supply.	
22	<u>(c)</u> <u>A su</u>	pplier shall not be subject to arrest, prosecution, or penalty	in any manner for
23	producing, posse	essing, distributing, or dispensing cannabis or cannabis-infu	used products in a
24	manner consister	nt with this Article.	
25	(d) When	an employee, officer, or agent of the State makes a finding	, determination, or
26	otherwise consid	lers a qualified patient or designated caregiver's possession of	or use of cannabis,
27		fused product, the employee, officer, or agent may not con	÷
28	patient or design	ated caregiver's possession or use any differently than the la	wful possession or
29	• •	cribed controlled substance, if the qualified patient or desi	gnated caregiver's
30	-	e complies with this Article.	
31		ng in this Article shall be construed to extend the protection	
32		uding a qualified patient, a designated caregiver, or a supp	
33		e, possess, manufacture, produce, use, sell, distribute, disp	pense, or transport
34		nner that is not consistent with this Article.	
35		Smoking and vaping prohibited in certain places.	
36		ng in this Article shall authorize a registry identification can	
37		f cannabis or the vaping of cannabis for medical use in the fo	ollowing places:
38	$\frac{(1)}{(2)}$	In a public place or a place open to the public.	
39	$\frac{(2)}{(2)}$	In any place of employment.	
40	$\frac{(3)}{(4)}$	In a vehicle.	1 1 1 1
41	<u>(4)</u>	In or within 1,000 linear feet of the property line of a	church, unless the
42	(5)	medical use occurs within a private residence.	11 f
43	<u>(5)</u>	In or within 1,000 linear feet of the property line of a ch defined in $C = 110.86(2)$, upless the medical use accur	
44 45		defined in G.S. 110-86(3), unless the medical use occur	÷
		residence. When a private residence is a child care facility	ty, the smoking of
46 47	(6)	cannabis and the vaping of cannabis is prohibited. In or within 1,000 linear feet of the property line of a public	school unit or ony
47 48	<u>(6)</u>	nonpublic school as defined in Part 1 or Part 2 of Article 3	
48 49			
49 50		of the General Statutes, unless the medical use occurs	<u>, within a private</u>
50		residence.	

	General Assem	bly Of North Carolina	Session 2021
1 2 3 4 5 6	<u>(7)</u>	In or within 1,000 linear feet of the property line of a the facilities of The University of North Carolina and facilities as defined in G.S. 143-597(a)(6), unless the within a private residence. Smoking or vaping is perm that are used for medical or scientific research to the e vaping is an integral part of the research. Smoking or v	the grounds of those e medical use occurs nitted inside buildings extent that smoking or aping permitted under
7		this subdivision shall be confined to the area where	the research is being
8		<u>conducted.</u>	waning of somethis in
9 10		individual who engages in the smoking of cannabis or the	
10 11	twenty-five dolla	section shall be guilty of an infraction and punished by a $\frac{1}{2}$. The of not more than
12	· · · ·	Violations; penalties; and enhanced sentence for the	rafficking related to
12		cal cannabis.	Tamental Telateu to
13 14		person who manufactures, sells, delivers, or posse	esses with intent to
14		l, or deliver cannabis in violation of this Article at a medi	
16		ty shall be punished as a Class G felon.	
17	-	person who creates, sells, delivers, or possesses with in	tent to sell or deliver
18		abis in violation of this Article at a medical cannabis center	
19		d as a Class H felon.	t of production facility
20		person who possesses an amount of cannabis up to $1 \frac{1}{2}$	ounces in violation of
21		medical cannabis center or production facility, shall be de	
22	A1 misdemeano	- · · ·	<u> 8)</u>
23		person who possesses an amount of cannabis that exc	eeds 1 $1/2$ ounces in
24	· · · ·	Article, at a medical cannabis center or production facility	
25	a Class H felon.		<u> </u>
26	(e) Any	person that provides the Department with false or misle	eading information in
27	relation to a re	gistry identification card or license shall be deemed	guilty of a Class 1
28	misdemeanor.		
29	<u>(f)</u> <u>Any</u>	person who has been issued a valid registry identification	n card who is found to
30		of cannabis in violation of this Article shall be punished a	
31		person is convicted of a violation of G.S. 90-95(h)(1), and	
32		mitted at a medical cannabis center or production facility	
33		bis center or production facility, then the person shall be	•
34		lass higher than the principal felony for which the person	
35		onths will be added to the mandatory minimum sentence. N	
36	*	section shall be sentenced at a level higher than a Class C	•
37		or the felony shall allege in that indictment or information	. .
38		n enhancement under this section. One pleading is sufficient	ent for all felonies that
39 40	are tried at a sing		tion many dad by law
40		e penalties may be imposed in addition to any other penalties.	ties provided by law.
41 42		North Carolina medical cannabis verification system.	a sagura wab basad
42 43		<u>ication System. – The Department shall establish</u> em. The verification system shall allow authorized Depart	
43 44		enforcement personnel, and medical cannabis centers	.
45		rd number to determine whether the number corresponds	
46		ation card. For the purposes of this subsection, the system	
47	<u>(1)</u>	Whether the registry identification card is valid.	<u></u>
48	(2)	The name, address, and date of birth of the cardholder.	
49	(3)	A photograph of the cardholder, if required by Departm	nent rules.
50	(4)	Whether the cardholder is a qualifying patient or a desi	

	General Assem	bly Of North Carolina	Session 2021
1	<u>(5)</u>	The registry identification card number of any associat	ted qualifying patients
2		or designated caregivers.	
3	<u>(6)</u>	Only if accessed by a medical cannabis center em	ployee or authorized
4		Department personnel, the amount of cannabis and can	
5		dispensed in the past 30 days.	<u> </u>
6	(7)	The delivery method of the cannabis.	
7		ication System Access. – No person or entity may have	access to information
8		e Department's verification system, except for an author	
9		he course of official duties or a State or local law enfor	-
10		al duties related to a person who claims to be a qualifying	
11		ier, or supplier agent engaged in conduct authorized in this	
12		irement to Check Before cannabis or cannabis-infu	
13	· · · ·	gistry identification cardholder, a medical cannabis center	
14	_	system and determine that:	1 V
15	(1)	The registry identification card presented at the medi-	cal cannabis center is
16	<u></u>	valid.	
17	(2)	Each person presenting a registry identification card is	s the person identified
18		on the registry identification card presented to the me	-
19		employee.	
20	<u>(3)</u>	The amount to be dispensed would not cause a qualify	ing patient, directly or
21		via the qualifying patient's designated caregiver, to	
22		obtaining no more than an adequate supply of cannabi	
23		products during any 30-day period.	
24	<u>(4)</u>	The cannabis to be dispensed complies with the deliver	ry method.
25	(5)	After making the determinations required in subdivision	-
26		subsection, but before dispensing cannabis or cannabis	
27		registry identification cardholder, a medical cannabis	-
28		enter the following information in the verification syste	
29		a. How much cannabis or cannabis-infused produc	
30		the registry identification cardholder.	<u>1</u>
31		b. Whether the cannabis or cannabis-infused prod	uct is to be dispensed
32		directly to the qualifying patient or to the	-
33		designated caregiver.	
34		c. The date and time the cannabis or cannabis-int	fused product is to be
35		dispensed.	-
36		d. The registry identification number of the medica	al cannabis center that
37		dispensed the cannabis or cannabis-infused proc	
38	" <u>§ 90-113.128.</u>	Inspections; security measures.	
39	(a) Inspe	ection. – The Department shall perform annual inspections	of the premises of any
40	person licensed	under this section, including any production facility or me	edical cannabis center.
41	All production f	facilities and medical cannabis centers owned and operation	ated by a supplier are
42		om inspection by the Department, and the North Caro	
43	Investigation in	accordance with rules adopted by the Commission, which	shall be developed by
44	the Commission	after consulting with and receiving input from the North	Carolina State Bureau
45	of Investigation.		
46	(b) Secur	rity Measures. –	
47	(1)	Suppliers shall implement appropriate security measur	es in accordance with
48		rules adopted by the Commission, which shall b	e developed by the
49		Commission after consulting with and receiving input fr	om the North Carolina
50		State Bureau of Investigation, designed to deter and	prevent the theft of

General A	ssemb	ly Of North Carolina	Session 2021
		cannabis and cannabis-infused products and unaut	thorized entrance into areas
		containing cannabis or cannabis-infused products.	
	<u>(2)</u>	All production facilities shall conduct cultivation,	=
	<u>_/</u>	packaging of cannabis and cannabis-infused prod	
		facility at a physical address provided to the Com	
		cannabis supplier license application process. A p	-
		be accessed by a supplier or a supplier's empl	
		Department personnel, law enforcement personnel	
		adults who are 21 years of age and older who are	• • •
		or supplier's agents or principals.	accompanied of a supprior
'8 90-113.1	129. N	Aedical cannabis center hours; location and age	restrictions.
		. – A medical cannabis center licensed under this A	
		ed products between the hours of 7:00 P.M. and 7:0	
		ion. – A medical cannabis center shall not be located	
		of any of the following places:	
	<u>(1)</u>	<u>A church.</u>	
	(1) (2)	A child care facility as defined in G.S. 110-86(3).	
	$\frac{(2)}{(3)}$	A public school unit or any nonpublic school as d	
	<u>(0)</u>	Article 39 of Chapter 115C of the General Statute	
	(4)	A community college or the facilities of The Unive	
	<u></u>	the grounds of those facilities as defined in G.S. 1	-
(c)	Age	- An individual must be 18 years old or older to ente	
		lual is a registry identification cardholder.	,,, _,
		Cesting of cannabis and cannabis-infused produc	ets.
		epartment shall establish standards for and shall lic	
		es to test cannabis and cannabis-infused products that	
An indepe	ndent	testing laboratory shall analyze a representative	sample of all cannabis or
cannabis-ir	nfused	products before the sale or transfer to a medical can	nabis center by a production
		bendent testing laboratory shall report the results of	
Departmen	t to th	e Department.	
<u>(b)</u>	An in	dependent testing laboratory shall be responsible fo	or selecting, picking up, and
testing proc	duct sa	mples.	
<u>(c)</u>	The D	epartment shall adopt rules to establish, at a minim	um, the following:
	<u>(1)</u>	Standards for testing cannabis and cannabis pro-	ducts, including specifying
		prohibited concentrations of heavy metals, pesti	icides, microbes, and other
		contaminants that are injurious to human health.	
	<u>(2)</u>	Standards for independent testing laboratories,	including requirements for
		equipment and qualifications for personnel.	
	<u>(3)</u>	Standards and requirements necessary for an inde	ependent testing laboratory
		to be licensed.	
	(4)	Remedial actions to be taken if the representative	e sample does not meet the
		standards established by the Department.	
	<u>(5)</u>	A fee schedule for independent testing laboratorie	<u>es.</u>
		Advertising.	
	-	roduction facility or medical cannabis center logo, si	
		ectful, and medically focused and shall not app	
		es or attempts at humor. Suppliers are prohibited fr	
-		abis or cannabis-infused products in or on their logo	1 0 0
	-	ot use neon-colored signage, logos, or packaging of	
		es. The supplier shall submit any logo or sign for re	eview to the Department in
accordance	e with	Department rules.	

G	eneral A	Asseml	oly Of North Carolina	Session 2021
1	(b)	Notw	ithstanding any municipal or county ordinance prohibiting sign	age, the medical
			shall only use signage that includes the medical cannabis cent	
	nd hours			· • •
4 5 5 7	<u>(c)</u>	(1) (2) (3)	dical cannabis center may maintain a website that includes info The location and hours of operation of the medical cannabis The product or service available at the medical cannabis cent The personnel affiliated with the medical cannabis center.	center.
		<u>(4)</u>	The best practices that the medical cannabis center upholds.	
		<u>(5)</u>	Educational material related to the medical use of cannabis, a Department.	-
su	<u>(d)</u>	-	roduction facilities and medical cannabis centers owned and	
			aintain a discreet, professional appearance that is compatib	-
			tures or land uses within the immediate area, including requiren acility or medical cannabis center in a manner to prevent blig	
di	minishn	nent, oi	impairment of property values within the vicinity.	
	<u>(e)</u>		Department shall adopt rules to define standards for a medical of	
			nd logo to ensure a medical rather than recreational disposition	L <u>.</u>
" <u>\$</u>	<u>90-113 90-1000 9000000000000000000000000000000</u>		Packaging of cannabis and cannabis-infused products.	
	<u>(a)</u>		itions. – The following definitions apply in this section:	
		<u>(1)</u>	Child-resistant packaging. – A package that is designed or c	
			significantly difficult for children under 5 years of age to open	
			for normal adults to use properly, substantially similar to tho	
			C.F.R. § 1700.20 (1995), opaque so that the packaging do	
			product to be seen without opening the packaging material, a	
			any product intended for more than a single use or con	taining multiple
		(\mathbf{a})	servings.	41- :4 1 -:-1-
		<u>(2)</u>	Exit packaging. – A sealed, child-resistant packaging recep	
			pre-packaged cannabis products are placed at the retail po- medical cannabis center.	onnt of sale at a
	(b)	Supp	iers shall safely package and accurately label cannabis or a	connobic infused
nr			ns sold at a medical cannabis center shall be properly labeled	
-			ckaging. Labels shall not include strain names but may include	
		-	for identification. Each label shall comply with State laws an	
	inimum		± •	<u>a ruies and, at a</u>
<u>111</u>	mmun	<u>(1)</u>	The name of the medical cannabis center.	
		$\frac{(1)}{(2)}$	The percentage of tetrahydrocannabinol and the percentage	e of cannabidiol
		<u>_/</u>	within a profile tolerance range of ten percent (10%). For	
			products, the cannabinoid profile should be listed by milligra	
		<u>(3)</u>	The name of the production facility.	p
		(4)	A conspicuous statement printed in all capital letters and	in a color that
		<u> </u>	provides a clear contrast to the background that reads, "NOT	
			FOR MEDICAL USE ONLY. KEEP OUT OF THE REACH	
			AND ANIMALS.".	
		(5)	The length of time it typically takes for the product to take effective to take effe	ffect.
		(6)	For edible cannabis-infused products, the disclosure of ingr	
			allergens, nutritional fact panel, and a standard symbol in	
			product contains cannabis.	
	<u>(c)</u>	<u>All</u> c	annabis products purchased in medical cannabis centers sha	<u>all be placed in</u>
<u>ch</u>	nild-resis	stant ex	it packaging before leaving the medical cannabis center.	
	<u>(d)</u>	The I	Department shall adopt rules to do, at a minimum, all of the foll	lowing:

_	General Assemb	oly Of North Carolina	Session 202
	(1)	Establish requirements and procedures for the safe,	appropriate, and accurat
		packaging and labeling of cannabis and cannabis-int	fused products for huma
		consumption, including prohibiting the use of any i	mages designed or likel
		to appeal to minors, including cartoons, toys, anima	als, or children, any othe
		likeness to images, characters, or phrases that are po	opularly used to advertis
		to children, or any imitation of candy packaging or l	labeling.
	<u>(2)</u>	Establish requirements to ensure that cannabis and c	annabis-infused product
		for human consumption are designed, marketed, an	nd packaged in a manne
		that is appropriate for a medicinal product and	that does not resemble
		commercially sold candies or other food that is typic	-
	<u>(3)</u>	Establish restrictions on the forms and appearance of	
		products in order to reduce their appeal to minors, inc	
		cannabis products in the shapes of cartoons, toys, an	<u>imals, or people.</u>
		Disposal of cannabis.	
		oduction center cannabis by-product, cannabis scrap	
		listribution to a medical cannabis center or independe	
		disposed of in accordance with Department rules. Doc	
	· ·	l be retained by the production center for a period of n	-
		shall maintain a record of the date of destruction and	-
		dical cannabis center shall destroy all cannabis and c	
		to registry identification cardholders in accordance wi	-
		center shall retain documentation of the destruction	
		one year. The medical cannabis center shall maintai	n a record of the date of
		<u>ne amount destroyed.</u>	nno du oto theot one noturne
		<u>dical cannabis center shall destroy all unused cannabis</u> nnabis center by a former qualifying patient who no lo	
		bis or the former qualifying patient's caregiver.	<u>niger quaimes for the us</u>
		North Carolina Cannabis Research Program.	
		ie intent of the General Assembly that The University	of North Carolina Syste
		tive, scientific research regarding the administ	-
		products as part of medical treatment. The Universit	
		to be known as the North Carolina Cannabis Research	-
		esearch conducted under this section may involve the	
		and labeling standards for cannabis dispensed through	* *
		system; sound advice and recommendations on the b	
		ivation of cannabis; and analysis of genetic and healing	
		cannabis to determine which strains may be best suited	
	or treatment.		*
	" <u>§ 90-113.135.</u> I	Educational campaign.	
	(a) The l	Department, in consultation with medical professi	onals, shall develop a
	educational cam	paign about the regulated medical cannabis supply	system. The education
	campaign shall	be regularly advertised through television, online	e, or social media. Th
	educational camp	baign must include:	
	<u>(1)</u>	The debilitating medical conditions which may be the	reated with medical use.
	<u>(2)</u>	Potential benefits and risks of the use of cannab	ois and cannabis-infuse
		products.	
	<u>(3)</u>	A notification that cannabis and cannabis-infused pro	oducts are for a qualifyir
		patient's use only and that they should not be donated	d or otherwise supplied t

	General Assem	bly Of North Carolina	Session 2021
1	(b) The I	Department shall make the information identified in subsection (a	a) of this section
2		with a link to the information conspicuously located on the	
3	website.	with a link to the information conspicuously foculed on a	<u>le Department s</u>
4		North Carolina Medical Cannabis Program Fund.	
5		ablished within the Department the North Carolina Medical Ca	nnahis Program
6		he availability of funds necessary to carry out the Department's	
7		e. All monies collected pursuant to this Article shall be deposite	*
8		be used for direct and indirect costs associated with the i	
9		and enforcement of this Article. Revenues generated in excess	
10		ement, administer, and enforce this Article shall be annually d	· · · · · · · · · · · · · · · · · · ·
11	State General Fu		istributed to the
12		Self-supporting requirement; use of excess revenue.	
12		Supporting Requirement. – The system revenues from license for	ees and monthly
14		es are appropriated to the Commission to fund in the following of	
15	(1)	Costs associated with establishing and operating the reg	
16	<u>\</u>	cannabis supply system established under this section.	, diated incurcai
17	(2)	The registry system established under G.S. 90-113.119.	
18	(3)	The North Carolina Cannabis Research Program est	ablished under
19	<u></u>	G.S. 90-113.134, limited to an amount of funding to be det	
20		Commission.	
21	(b) Use of	of Excess Revenues. – Any revenues remaining at the end of a	fiscal year after
22		a fully funds the priorities set forth in subsection (a) of this	
23	transferred at the	e beginning of the subsequent fiscal year to the General Fund.	
24	"§ 90-113.138.	Reserved for future codification purposes.	
25	" <u>§ 90-113.139.</u>	Reserved for future codification purposes.	
26	" <u>§ 90-113.140.</u>	Annual report.	
27	<u>(a)</u> The l	Department, in consultation with the Commission and the Advis	<u>ory Board, shall</u>
28	report annually	on the effectiveness of the medical cannabis program operated	pursuant to this
29	Article and rec	ommendations for any changes to the program. The report	t shall, without
30	disclosing any	identifying information about cardholders, physicians, qua	alified patients,
31		givers, or suppliers, contain the following, at a minimum:	
32	<u>(1)</u>	The number of registry identification card applications subm	itted, approved,
33		and renewed.	
34	<u>(2)</u>	The number of qualifying patients and designated caregivers	served by each
35		medical cannabis center during the report year.	
36	<u>(3)</u>	The nature of the debilitating medical conditions of the qualify	ving patients and
37		a breakdown of qualifying patients by age group.	
38	<u>(4)</u>	The new debilitating medical conditions added by the Advisor	
39	<u>(5)</u>	The efficacy of or satisfaction with cannabis and cannabis-i	•
40		on a yes-no questionnaire as submitted by qualifying patients	
41		anonymous survey, which may be conducted online or the	hrough medical
42		cannabis centers.	
43	<u>(6)</u>	The number of registry identification cards denied, suspended	
44	<u>(7)</u>	The number of physicians providing written certifications	for qualitying
45	$\langle 0 \rangle$	patients.	1.
46	<u>(8)</u>	The number of suppliers, production facilities, and medical of	cannabis centers
47 48		by county.	mittaa ar II 141
48 40		report shall be submitted to the Joint Legislative Oversight Com	
49 50		vices and to the Joint Legislative Oversight Committee on Just er 1 of each year, beginning in 2022.	suce and Public
50 51		Construction of Article.	
51	<u>8 70-113.141.</u>		

This Article shall not be construed to do any of the following: 1 Allow for a violation of any law other than for conduct in compliance with the provisions of this Article. 4 (2) Affect or repeal laws relating to nonmedical use, possession, production, or sale of cannabis. 6 (3) Authorize the use of cannabis by anyone other than a qualified patient. 7 (4) Permit the operation of any vehicle, aircraft, train, or boat while under the influence of cannabis. 8 (1) Require the violation of federal law or purport to give immunity under federal law. 9 (5) Require any accommodation of any on-site medical use of cannabis in any public place. 10 (a) Require any accommodation or detention facility or place of education or employment, or of smoking or vaping cannabis in any public place. 11 (6) Require a health insurance provider, health care plan, property and casualty insurer, or medical assistance program to be liable for or reimburse a claim for the medical use of cannabis. Consultations in which physicians diagnose debilitating medical conditions and complete written certifications shall be rear to a qualified patient, designated caregiver, physician, supplier, or supplier's agents or employces. 19 (8) Affect or repeal laws relating to negligence or professional malgractice on the part of a qualified patient, designated caregiver, physician, supplier, or supplier's agents or employces.		General Assemb	ly Of North Carolina	Session 2021
2 (1) Allow for a violation of any law other than for conduct in compliance with the provisions of this Article. 3 Affect or repeal laws relating to nonmedical use, possession, production, or sale of cannabis. 6 (3) Authorize the use of cannabis by anyone other than a qualified patient. 7 (4) Permit the operation of any vehicle, aircraft, train, or boat while under the influence of cannabis. 9 (5) Require the violation of federal law or purport to give immunity under federal law. 10 (aw. 11 (6) Require the violation of federal law or purport to give immunity under federal law. 12 correctional institution or detention facility or place of education or employment, or of smoking or vaping cannabis in any public place. 14 (7) Require a health insurance provider, health care plan, property and casualty insurer, or medical assistance program to be liable for or reinburse a claim for the medical laws of cannabis. Consultations in which physicians diagnose debilitating medical laws of the provider, health care facility. 18 reinbursed consistent with any other visit to a health care facility. 19 (8) Affect or repeal laws relating to negligenee or professional malpractice on the part of a qualified patient, designated caregiver, physician, supplier, or supplier's agents or employees. 22 (9) Impair the ability of a community association to prohibit or limit smoking or vaping of cannabis on his or her private property.	1	This Article s	hall not be construed to do any of the following:	
3 provisions of this Article. 4 (2) Affect or repeal laws relating to nonmedical use, possession, production, or sale of cannabis. 6 (3) Authorize the use of cannabis by anyone other than a qualified patient. 7 (4) Permit the operation of any vehicle, aircraft, train, or boat while under the influence of cannabis. 7 (4) Permit the operation of federal law or purport to give immunity under federal law. 10 (5) Require the violation of federal law or purport to give immunity under federal law. 11 (6) Require any accommodation of any on-site medical use of cannabis in any correctional institution or detention facility or place of education or employment, or of smoking or vaping cannabis in any public place. 12 remedical assistance provider, health care plan, property and casualty insure, or medical assistance program to be liable for or reimburse a claim for the medical use of cannabis. Consultations in which physicians diagnose debilitating medical conditions and complete written certifications shall be reimbursed consistent with any other visit to a health care facility. 19 (8) Affect or repeal laws relating to negligence or professional malpractice on the part of a qualified patient, designated caregiver, physician, supplier, or supplier's agents or employees. 22 (9) Impair the ability of a community association to prohibit or limit smoking or vaping of cannabis on is a common area through the community association's			• •	ompliance with the
4 (2) Affect or repeal laws relating to nonmedical use, possession, production, or sale of cannabis. 6 (3) Authorize the use of cannabis by anyone other than a qualified patient. 7 (4) Permit the operation of any vehicle, aircraft, train, or boat while under the influence of cannabis. 9 (5) Require the violation of federal law or purport to give immunity under federal law. 10 (aw. (6) Require any accommodation of any on-site medical use of cannabis in any correctional institution, or detention facility or place of education or employment, or of smoking or vaping cannabis in any public place. 14 (7) Require a health insurance provider, health care plan, property and casualty insurer, or medical assistance program to be liable for or reimburse a claim for the medical use of cannabis. Consultations in which physicians diagnose debilitating medical conditions and complete written certifications shall be reimbursed consistent with any other visit to a health care facility. 19 (8) Affect or repeal laws relating to negligence or professional malpractice on the part of a qualified patient. designated carepiver, physician, supplier, or supplier's agents or employees. 20 Impair the ability of any party to prohibit or limit smoking or vaping of cannabis in a common area through the community association's declaration or bylaws. 78 90-113.113 Impair the asility of any party to prohibit or limit smoking or yaping of cannabis in a common area through the compre		<u></u>		<u> </u>
 sale of cannabis. Authorize the use of cannabis by anyone other than a qualified patient. Authorize the use of cannabis by anyone other than a qualified patient. Bequire the violation of any vehicle, aircraft, train, or boat while under the influence of cannabis. Require the violation of federal law or purport to give immunity under federal law. Require any accommodation of any on-site medical use of cannabis in any correctional institution or detention facility or place of education or employment, or of smoking or vaping cannabis in any public place. Require a health insurance provider, health care plan, property and casualty insurer, or medical assicance program to be liable for or reimburse a claim for the medical use of cannabis. Consultations in which physicians diagnose debilitating medical conditions and complete written certifications shall be reimbursed consistent with any other visit to a health care facility. Affect or repeal laws relating to negligence or professional mappractice on the supplier's agents or employees. Impair the ability of any party to prohibit or limit smoking or vaping of cannabis on his or her private property. Impair the ability of a community association to prohibit or limit smoking or vaping of cannabis on his or her private property. Impair the ability of a community association to prohibit or limit smoking or vaping of cannabis in a common area through the community association's declaration or bylaws. SECTION 2.(a) The initial appointments made to the Compassionate Use Advisory Board under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)h. shall be two years. Members appointed under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)h. shall be two years. Members appointed under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)f. the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)f. th		(2)	±	on, production, or
 Gauthorize the use of cannabis by anyone other than a qualified patient. Permit the operation of any vehicle, aircraft, train, or boat while under the influence of cannabis. Require any accommodation of fay on-site medical use of cannabis in any correctional institution or detention facility or place of caucation or employment, or of smoking or vaping cannabis in any public place. Require a health insurance provider, health care plan, property and casualty insurer, or medical assistance program to be liable for or reimburse a claim for the medical use of cannabis. Consultations in which physicians diagnose debilitating medical conditions and complete written certifications shall be reimbursed consistent with any other visit to a health care facility. (1) Require a health insurance provider, health care plan, property and casualty insurer, or medical assistance program to be liable for or reimburse a claim for the medical use of cannabis. Consultations in which physicians diagnose debilitating medical conditions and complete written certifications shall be reimbursed consistent with any other visit to a health care facility. (2) Impair the ability of any party to prohibit or limit smoking or vaping of cannabis on his or her private property. (10) Impair the ability of a community association to prohibit or limit smoking or vaping of cannabis on bis or her private property. The provisions of this Article are severable. If any provision of this Article is held invalid by a court of Competent jurisdiction, the invalidity shall not affect other provisions of this Article which care fact without the invalid provision." SeCTION 2.(a) The initial appointments made to the Compassionate Use Advisory Board under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)f. shall be two years. Members appointed under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)f. hall be two years. Members appointed pursuant to G.S. 90-1				<u> </u>
 (4) Permit the operation of any vehicle, aircraft, train, or boat while under the influence of cannabis. (5) Require the violation of federal law or purport to give immunity under federal law. (6) Require any accommodation of any on-site medical use of cannabis in any correctional institution or detention facility or place of education or employment, or of smoking or vaping cannabis in any public place. (7) Require a health insurance provider, health care plan, property and casualty insurer, or medical assistance program to be liable for or reimburse a claim for the medical use of cannabis. Consultations in which physicians diagnose debilitating medical conditions and complete written certifications shall be reimbursed consistent with any other visit to a health care facility. (8) Affect or repeal laws relating to negligence or professional malpractice on the part of a qualified patient, designated caregiver, physician, supplier, or supplier's agents or employees. (9) Impair the ability of any party to prohibit or limit smoking or vaping of cannabis on his or her private property. (10) Impair the ability of a community association to prohibit or limit smoking or vaping of cannabis in a common area through the community association's declaration or bylaws. *§00-113.113 (a)(1)g, and (a)(1), b, prior to the rissuance of identification cards shall represent a potential registry identification cards shall represent a potential registry identification cards of a licensed supplier appointed pursuant to G.S. 90-113.113 (a)(1)g, and (a)(1), b, prior to the issuance of identification cards shall represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis and a parent of a minor qualified patient with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113 (a)(1), a, (a)(1),	6	(3)		fied patient.
 influence of cannabis. (5) Require the violation of federal law or purport to give immunity under federal law. (6) Require any accommodation of any on-site medical use of cannabis in any correctional institution or detention facility or place of education ary employment, or of smoking or vaping cannabis in any public place. (7) Require a health insurance provider, health care plan, property and casualty insurer, or medical use of cannabis. Consultations in which physicians diagnose debilitating medical conditions and complete written certifications. shall be reimbursed consistent with any other visit to a health care facility. (8) Affect or repeal laws relating to negligence or professional malpractice on the part of a qualified patient, designated caregiver, physician, supplier, agents or employees. (9) Impair the ability of any party to prohibit or limit smoking or vaping of cannabis in a common area through the community association's declaration or bylaws. *S0-113.142. Severability. *Severability. *Berroixisons of this Article are severable. If any provision of this Article is held invalid by a court of competent jurisdiction, the invalid provision." SECTION 2.(a) The initial appointments made to the Compassionate Use Advisory Board under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)i. shall be two years. Members appointed under G.S. 90-113.113(a)(1)g. and (a)(1)h. prior to the issuance of identification cards shall represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis and a parent of a minor qualified patient with a debilitating medical condition who intends to use cannabis. A parent da (a)(1)f. the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)c., (a)(1). Mich can be given effect without the invalid provision." SECTION 2.(b) The inititial appointments made to	7		••••	-
 law. (6) Require any accommodation of any on-site medical use of cannabis in any correctional institution or detention facility or place of education or employment, or of smoking or vaping cannabis in any public place. (7) Require a health insurance provider, health care plan, property and casualty insurer, or medical assistance program to be liable for or reimburse a claim for the medical use of cannabis. Consultations in which physicians diagnose debilitating medical conditions and complete written certifications shall be reimbursed consistent with any other visit to a health care facility. (8) Affect or repeal laws relating to negligence or professional malpractice on the part of a qualified patient, designated caregiver, physician, supplier, or supplier's agents or employees. (9) Impair the ability of any party to prohibit or limit smoking or vaping of cannabis on his or her private property. (10) Impair the ability of a community association to prohibit or limit smoking or vaping of cannabis on his or her private property. The provisions of this Artricle are severable. If any provision of this Article is held invalid by a court of competent jurisdiction, the invalidity shall not affect other provisions of this Article which can be given effect without the invalid provision. SECTION 2.(a) The initial appointments made to the Compassionate Use Advisory Board under G.S. 90-113.113 (a)(1)g, (a)(1)h, and (a)(1)h, prior to the issuance of identification cards shall represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1)g, (a)(1), (a)(1), hishall be tory years; for each member appointed pursuant to G.S. 90-113.113(a)(1)g, (a)(1), (a)(1), (a)(1), (a)(1), (a)(2) and (a)(3) shall be one year. Subsequent aponinteent shall be for the full four-years; the initial term	8		influence of cannabis.	
11 (6) Require any accommodation of any on-site medical use of cannabis in any correctional institution or detention facility or place of education or employment, or of smoking or vaping cannabis in any public place. 12 (7) Require a health insurance provider, health care plan, property and casualty insurer, or medical assistance program to be liable for or reimburse a claim for the medical use of cannabis. Consultations in which physicians diagnose debilitating medical conditions and complete written certifications shall be reimbursed consistent with any other visit to a health care facility. 19 (8) Affect or repeal laws relating to negligence or professional malpractice on the part of a qualified patient, designated caregiver, physician, supplier, or supplier's agents or employees. 20 (9) Impair the ability of a community association to prohibit or limit smoking or vaping of cannabis in a common area through the community association's declaration or bylaws. 23 ************************************	9	<u>(5)</u>	Require the violation of federal law or purport to give immu	unity under federal
12 correctional institution or detention facility or place of education or employment, or of smoking or vaping cannabis in any public place. 14 (7) Require a health insurance provider, health care plan, property and casualty insurer, or medical assistance program to be liable for or reimburse a claim for the medical use of cannabis. Consultations in which physicians diagnose debilitating medical conditions and complete written certifications shall be reimbursed consistent with any other visit to a health care facility. 18 reimbursed consistent with any other visit to a health care facility. 19 (8) Affect or repeal laws relating to negligence or professional malpractice on the part of a qualified patient, designated caregiver, physician, supplier, or supplier's agents or employees. 20 (9) Impair the ability of any party to prohibit or limit smoking or vaping of cannabis on his or her private property. 24 (10) Impair the ability of a community association to prohibit or limit smoking or vaping of cannabis in a common area through the community association's declaration or bylaws. 27 § 90-113.142 , Wererability. 28 SecTION 2.(a) The initial appointments made to the Compassionate Use Advisory Board under G.S. 90-113.113 shall be made not later than 45 days after the effective date of this act. In order to provide for the staggering of terms, the initial term for each member appointed under G.S. 90-113.113 (a)(1)g., (a)(1)h., and (a)(1)f. is hall be two years. Members appointed pursuant to G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)f. the initial empointed pursuant to G.	10		law.	
 mployment, or of smoking or vaping cannabis in any public place. (7) Require a health insurance provider, health care plan, property and casually insurer, or medical assistance program to be liable for or reimburse a claim for the medical use of cannabis. Consultations in which physicians diagnose debilitating medical conditions and complete written certifications shall be reimbursed consistent with any other visit to a health care facility. (8) Affect or repeal laws relating to negligence or professional malpractice on the part of a qualified patient, designated caregiver, physician, supplier, or supplier's agents or employees. (9) Impair the ability of any party to prohibit or limit smoking or vaping of cannabis on his or her private property. (10) Impair the ability of a community association to prohibit or limit smoking or vaping of cannabis in a common area through the community association's declaration or bylaws. **590-113.142. Severability. The provisions of this Article are severable. If any provision of this Article is held invalid by a court of competent jurisdiction, the invalidity shall not affect other provisions of this Article which can be given effect without the invalid provision." SECTION 2.(a) The initial appointments made to the Compassionate Use Advisory Board under G.S. 90-113.113(a)(1)g. and (a)(1)h. prior to the issuance of identification cardis shall represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1)g. (a)(1)e., and (a)(1)f. the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)e. (a)(1)e., and (a)(1)f. the initial term shall be three years; and the initial term for member appointed pursuant to G.S. 90-113.113(a)(1)e. (a)(1)e., and (a)(1)f. the initial term shall be three years; and the initial term for m	11	<u>(6)</u>	Require any accommodation of any on-site medical use of	of cannabis in any
 (7) Require a health insurance provider, health care plan, property and casualty insurer, or medical assistance program to be liable for or reimburse a claim for the medical use of cannabis. Consultations in which physicians diagnose debilitating medical conditions and complete written certifications shall be reimbursed consistent with any other visit to a health care facility. (8) Affect or repeal laws relating to negligence or professional malpractice on the part of a qualified patient, designated caregiver, physician, supplier, or supplier's agents or employees. (9) Impair the ability of any party to prohibit or limit smoking or vaping of cannabis on his or her private property. (10) Impair the ability of a community association to prohibit or limit smoking or vaping of cannabis in a common area through the community association's declaration or bylaws. ** 590-113.142. Severability. ** 590-113.142. Severability. The provisions of this Article are severable. If any provision of this Article is held invalid by a court of competent jurisdiction, the invalidity shall not affect other provisions of this Article which can be given effect without the invalid provision." SECTION 2.(a) The initial appointments made to the Compassionate Use Advisory Board under G.S. 90-113.113 (a)(1), (a)(1), and (a)(1), shall be two years. Members appointed under G.S. 90-113.113(a)(1)g, (a)(1)h. and (a)(1)h. shall be two years. Members appointed pursuant to G.S. 90-113.113(a)(1)g, (a)(1)e, and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)c, and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)e, and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)e., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)e. and (a)(1)d. shall be four years; for each member appointe	12		correctional institution or detention facility or place	of education or
 insurer, or medical assistance program to be liable for or reimburse a claim for the medical use of cannabis. Consultations in which physicians diagnose debilitating medical conditions and complete written certifications shall be reimbursed consistent with any other visit to a health care facility. (8) Affect or repeal laws relating to negligence or professional malpractice on the part of a qualified patient, designated caregiver, physician, supplier, or supplier's agents or employees. (9) Impair the ability of any party to prohibit or limit smoking or vaping of cannabis on his or her private property. (10) Impair the ability of a community association to prohibit or limit smoking or vaping of cannabis in a common area through the community association's declaration or bylaws. * 590-113.142. Severability. The provisions of this Article are severable. If any provision of this Article is held invalid by a court of competent jurisdiction, the invalidity shall not affect other provisions of this Article which can be given effect without the invalid provision." SECTION 2.(a) The initial appointments made to the Compassionate Use Advisory Board under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)h. ishall be two years. Members appointed under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)h. ishall be two years. Members appointed pursuant to G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)f. the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)h., (a)(1)f. the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f. the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f. the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f. the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f.	13		employment, or of smoking or vaping cannabis in any publ	lic place.
16 for the medical use of cannabis. Consultations in which physicians diagnose 17 debilitating medical conditions and complete written certifications shall be 18 reimbursed consistent with any other visit to a health care facility. 19 (8) Affect or repeal laws relating to negligence or professional malpractice on the 20 supplier's agents or employees. 9) 21 supplier's agents or employees. 22 (9) Impair the ability of any party to prohibit or limit smoking or vaping of cannabis on his or her private property. 24 (10) Impair the ability of a community association to prohibit or limit smoking or vaping of cannabis in a common area through the community association's declaration or bylaws. 28 90-113.1142. Severability. 28 The provisions of this Article are severable. If any provision of this Article is held invalid by a court of competent jurisdiction, the invalid provision." 31 SECTION 2.(a) The initial appointments made to the Compassionate Use Advisory 32 Board under G.S. 90-113.113 (a)(1)g., (a)(1)h., and (a)(1)i. shall be two years. Members appointed ursuant to G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)i. shall be two years. Members appointed pursuant to G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)d. shall be four each member appointed pursuant to G.S. 90-113.113(a)(1)a., (a)(1)c., and (a)(1)d. shall be a prospective supplier. In order to allow for the staggering of terms,	14	<u>(7)</u>	Require a health insurance provider, health care plan, pro	perty and casualty
17 debilitating medical conditions and complete written certifications shall be reimbursed consistent with any other visit to a health care facility. 19 (8) Affect or repeal laws relating to negligence or professional malpractice on the part of a qualified patient, designated caregiver, physician, supplier, or supplier's agents or employees. 21 (9) Impair the ability of any party to prohibit or limit smoking or vaping of cannabis on his or her private property. 23 (10) Impair the ability of a community association to prohibit or limit smoking or vaping of cannabis in a common area through the community association's declaration or bylaws. 24 (10) Impair the ability of a community association to prohibit or limit smoking or vaping of cannabis in a common area through the community association's declaration or bylaws. 27 *8 90-113.112 . The provisions of this Article are severable. If any provision of this Article is held invalid by a court of competent jurisdiction, the invalid provision." 28 BECTION 2.(a) The initial appointments made to the Compassionate Use Advisory 29 Board under G.S. 90-113.113 (a)(1), and (a)(1), is hall be two years. Members appointed pursuant to G.S. 90-113.113(a)(1), and (a)(1), is roir to the issuance of identification cards shall represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1), and (a)(1), shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1),	15		insurer, or medical assistance program to be liable for or	reimburse a claim
18 reimbursed consistent with any other visit to a health care facility. 19 (8) Affect or repeal laws relating to negligence or professional malpractice on the part of a qualified patient, designated caregiver, physician, supplier, or supplier's agents or employees. 22 (9) Impair the ability of any party to prohibit or limit smoking or vaping of cannabis on his or her private property. 24 (10) Impair the ability of a community association to prohibit or limit smoking or vaping of cannabis in a common area through the community association's declaration or bylaws. 27 "§ 90-113.142. Severability. 28 The provisions of this Article are severable. If any provision of this Article is held invalid by a court of competent jurisdiction, the invalidity shall not affect other provisions of this Article which can be given effect without the invalid provision." 29 Board under G.S. 90-113.113 shall be made not later than 45 days after the effective date of this act. In order to provide for the staggering of terms, the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)h. rior to the issuance of identification cards shall represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1)c., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)c., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)c., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.11	16		for the medical use of cannabis. Consultations in which pl	nysicians diagnose
 (8) Affect or repeal laws relating to negligence or professional malpractice on the part of a qualified patient, designated caregiver, physician, supplier, or supplier's agents or employees. (9) Impair the ability of any party to prohibit or limit smoking or vaping of cannabis on his or her private property. (10) Impair the ability of a community association to prohibit or limit smoking or vaping of cannabis in a common area through the community association's declaration or bylaws. *§ 90-113.142. Severability. The provisions of this Article are severable. If any provision of this Article is held invalid by a court of competent jurisdiction, the invalidity shall not affect other provisions of this Article without the invalid provision." SECTION 2.(a) The initial appointments made to the Compassionate Use Advisory Board under G.S. 90-113.113 (a)(1)g., (a)(1)h., prior to the issuance of identification cards shall represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)d., and (a)(1)f. the initial term shall be three years; and the initial (1), a, (a)(1)c., and (a)(1)f. the initial term shall be three years; and the initial (1), a, (a)(1)c., and (a)(1)f. the initial term shall be three years; and the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)c., and (a)(1)f. the initial term shall be three years; and the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)c., and (a)(1)f. the initial term shall be three years; and the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)c., and (a)(1)f. the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)c., and (a)(1)f. the initial term shall be three years; and the initial te	17		debilitating medical conditions and complete written cert	ifications shall be
 part of a qualified patient, designated caregiver, physician, supplier, or supplier's agents or employees. (9) Impair the ability of any party to prohibit or limit smoking or vaping of cannabis on his or her private property. (10) Impair the ability of a community association to prohibit or limit smoking or vaping of cannabis in a common area through the community association's declaration or bylaws. *§ 90-113.1142. Severability. The provisions of this Article are severable. If any provision of this Article is held invalid by a court of competent jurisdiction, the invalidity shall not affect other provisions of this Article which can be given effect without the invalid provision." SECTION 2.(a) The initial appointments made to the Compassionate Use Advisory Board under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)h. shall be two years. Members appointed under G.S. 90-113.113(a)(1)g., and (a)(1)h. prior to the issuance of identification cards shall represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial (erm for members appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant	18		reimbursed consistent with any other visit to a health care f	facility.
 supplier's agents or employees. (9) Impair the ability of any party to prohibit or limit smoking or vaping of cannabis on his or her private property. (10) Impair the ability of a community association to prohibit or limit smoking or vaping of cannabis in a common area through the community association's declaration or bylaws. "§ 90-113.142. Severability. The provisions of this Article are severable. If any provision of this Article is held invalid by a court of competent jurisdiction, the invalidity shall not affect other provisions of this Article without the invalid provision." SECTION 2.(a) The initial appointments made to the Compassionate Use Advisory Board under G.S. 90-113.113 (a)(1)g., (a)(1)h., and (a)(1)i. shall be two years. Members appointed under G.S. 90-113.113(a)(1)g., (a)(1)h., prior to the issuance of identification cards shall represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis and a parent of a minor qualified patient with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1)c., (a)(1)c., and (a)(1)d., shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)c., (a)(1)c., and (a)(1)d., the initial term shall be three years; and the initial term for member appointed pursuant to G.S. 90-113.113(a)(1)c., (a)(1)c., and (a)(1)d., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)c., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)c., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)c., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursua		<u>(8)</u>		
 (9) Impair the ability of any party to prohibit or limit smoking or vaping of cannabis on his or her private property. (10) Impair the ability of a community association to prohibit or limit smoking or vaping of cannabis in a common area through the community association's declaration or bylaws. *§ 90-113.142. Severability. The provisions of this Article are severable. If any provision of this Article is held invalid by a court of competent jurisdiction, the invalidity shall not affect other provisions of this Article which can be given effect without the invalid provision." SECTION 2.(a) The initial appointments made to the Compassionate Use Advisory Board under G.S. 90-113.113 (a)(1)g., (a)(1)h., and (a)(1)i. shall be two years. Members appointed under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)i. shall be two years. Members appointed pursuant to G.S. 90-113.113(a)(1)g., (a)(1)h. prior to the issuance of identification cards shall represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1)e., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)e., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)e., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)e., (a)(1)e., and (a)(1)f. the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f. the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f. the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f. the initial term shall be three years; and the initial term for members appo				<u>cian, supplier, or</u>
 cannabis on his or her private property. (10) Impair the ability of a community association to prohibit or limit smoking or vaping of cannabis in a common area through the community association's declaration or bylaws. "§ 90-113.142. Severability. The provisions of this Article are severable. If any provision of this Article is held invalid by a court of competent jurisdiction, the invalidity shall not affect other provisions of this Article which can be given effect without the invalid provision." SECTION 2.(a) The initial appointments made to the Compassionate Use Advisory Board under G.S. 90-113.113 shall be made not later than 45 days after the effective date of this act. In order to provide for the staggering of terms, the initial term for each member appointed under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)i. shall be two years. Members appointed pursuant to G.S. 90-113.113(a)(1)g. and (a)(1)h. prior to the issuance of identification cards shall represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1)c., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(1)b. (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(b). SECTION 2.(b) The in				
 (10) Impair the ability of a community association to prohibit or limit smoking or vaping of cannabis in a common area through the community association's declaration or bylaws. "§ 90-113.142. Severability. The provisions of this Article are severable. If any provision of this Article is held invalid by a court of competent jurisdiction, the invalidity shall not affect other provisions of this Article without the invalid provision." SECTION 2.(a) The initial appointments made to the Compassionate Use Advisory Board under G.S. 90-113.113 shall be made not later than 45 days after the effective date of this act. In order to provide for the staggering of terms, the initial term for each member appointed under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)i. shall be two years. Members appointed pursuant to G.S. 90-113.113(a)(1)g, and (a)(1)h. prior to the issuance of identification cards shall represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1)c., (a)(1)c., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)c., and (a)(1)f., the initial term she inhere appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)c., and (a)(1)f., the initial term she member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)c., and (a)(1)f., the initial term she member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)c., and (a)(1)f., the initial term she member appointed for members appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)c., and (a)(1)f., the initial term she member appointed for pursuant to G.S. 90-113.113(a)(1)b., (a)(1)c., and (a)(1)f., the initial term she member appointed for pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(b). SECTION 2.(b) The		<u>(9)</u>		<u>king or vaping of</u>
 vaping of cannabis in a common area through the community association's declaration or bylaws. "§ 90-113.142. Severability. The provisions of this Article are severable. If any provision of this Article is held invalid by a court of competent jurisdiction, the invalidity shall not affect other provisions of this Article which can be given effect without the invalid provision." SECTION 2.(a) The initial appointments made to the Compassionate Use Advisory Board under G.S. 90-113.113 shall be made not later than 45 days after the effective date of this act. In order to provide for the staggering of terms, the initial term for each member appointed under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)i. shall be two years. Members appointed pursuant to G.S. 90-113.113(a)(1)g. and (a)(1)h. prior to the issuance of identification cards shall represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1). prior to the licensing of suppliers shall be a prospective supplier. In order to allow for the staggering of terms, the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(1). SECTION 2.(b) The initial appointments made to the Medical Cannabis Production Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date of this act, and the Commission must hold their first meeting not later than 60 days after the effective date of this act, within 270 days of the first meeting, the Commission must adopt rules, as required by G.S. 90-113.118(k), and establish the medical cannabis supply sy				
26 declaration or bylaws. 27 "§ 90-113.142. Severability. 28 The provisions of this Article are severable. If any provision of this Article is held invalid by a court of competent jurisdiction, the invalidity shall not affect other provisions of this Article which can be given effect without the invalid provision." 31 SECTION 2.(a) The initial appointments made to the Compassionate Use Advisory 32 Board under G.S. 90-113.113 shall be made not later than 45 days after the effective date of this 33 act. In order to provide for the staggering of terms, the initial term for each member appointed 34 under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)i. shall be two years. Members appointed 35 pursuant to G.S. 90-113.113(a)(1)g. and (a)(1)h. prior to the issuance of identification cards shall 36 represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant 37 to G.S. 90-113.113(a)(1)i. prior to the licensing of suppliers shall be a prospective supplier. In 38 order to allow for the staggering of terms, the initial term for each member appointed pursuant 38 to G.S. 90-113.113(a)(1)i. (a)(1). shall be four years; for each member appointed pursuant 39 to G.S. 90-113.113(a)(1)b., (a)(1)c., and (a)(1)d. shall be four years; for each member appointed <td></td> <td><u>(10)</u></td> <td></td> <td></td>		<u>(10)</u>		
 ^{**}<u>§ 90-113.142. Severability.</u> The provisions of this Article are severable. If any provision of this Article is held invalid by <u>a court of competent jurisdiction, the invalidity shall not affect other provisions of this Article</u> which can be given effect without the invalid provision." SECTION 2.(a) The initial appointments made to the Compassionate Use Advisory Board under G.S. 90-113.113 shall be made not later than 45 days after the effective date of this act. In order to provide for the staggering of terms, the initial term for each member appointed under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)i. shall be two years. Members appointed pursuant to G.S. 90-113.113(a)(1)g. and (a)(1)h. prior to the issuance of identification cards shall represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis and a parent of a minor qualified patient with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1)i. prior to the licensing of suppliers shall be a prospective supplier. In order to allow for the staggering of terms, the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)a., (a)(1)c., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(b). SECTION 2.(b) The initial appointments made to the Medical Cannabis Production Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date of this act, and the Commission must hold their first meeti				unity association's
 The provisions of this Article are severable. If any provision of this Article is held invalid by a court of competent jurisdiction, the invalidity shall not affect other provisions of this Article which can be given effect without the invalid provision." SECTION 2.(a) The initial appointments made to the Compassionate Use Advisory Board under G.S. 90-113.113 shall be made not later than 45 days after the effective date of this act. In order to provide for the staggering of terms, the initial term for each member appointed under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)i. shall be two years. Members appointed pursuant to G.S. 90-113.113(a)(1)g. and (a)(1)h. prior to the issuance of identification cards shall represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1)i. prior to the licensing of suppliers shall be a prospective supplier. In order to allow for the staggering of terms, the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)a., (a)(1)c., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(2) and (a)(3) shall be one year. Subsequent appointments shall be for the full four-year term in accordance with G.S. 90-113.113(b). SECTION 2.(b) The initial appointments made to the Medical Cannabis Production Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date of this act, and the Commission must hold their first meeting not later than 60 days after the <li< td=""><td></td><td></td><td></td><td></td></li<>				
 a court of competent jurisdiction, the invalidity shall not affect other provisions of this Article which can be given effect without the invalid provision." SECTION 2.(a) The initial appointments made to the Compassionate Use Advisory Board under G.S. 90-113.113 shall be made not later than 45 days after the effective date of this act. In order to provide for the staggering of terms, the initial term for each member appointed under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)i. shall be two years. Members appointed pursuant to G.S. 90-113.113(a)(1)g. and (a)(1)h. prior to the issuance of identification cards shall represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis and a parent of a minor qualified patient with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1)i. prior to the licensing of suppliers shall be a prospective supplier. In order to allow for the staggering of terms, the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)a., (a)(1)c., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(b). SECTION 2.(b) The initial appointments made to the Medical Cannabis Production Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date of this act, and the Commission must hold their first meeting not later than 60 days after the effective date of this act. Within 270 days of the first meeting, the Commission must adopt rules, as required by G.S. 90-113.118(k), and establish the medical cannabis supply system, as required 				
 which can be given effect without the invalid provision." SECTION 2.(a) The initial appointments made to the Compassionate Use Advisory Board under G.S. 90-113.113 shall be made not later than 45 days after the effective date of this act. In order to provide for the staggering of terms, the initial term for each member appointed under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)i. shall be two years. Members appointed pursuant to G.S. 90-113.113(a)(1)g. and (a)(1)h. prior to the issuance of identification cards shall represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis and a parent of a minor qualified patient with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1)i. prior to the licensing of suppliers shall be a prospective supplier. In order to allow for the staggering of terms, the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)c., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(2) and (a)(3) shall be one year. Subsequent appointments shall be for the full four-year term in accordance with G.S. 90-113.113(b). SECTION 2.(b) The initial appointments made to the Medical Cannabis Production Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date of this act, and the Commission must hold their first meeting not later than 60 days after the effective date of this act. Within 270 days of the first meeting, the Commission must adopt rules, 				
 SECTION 2.(a) The initial appointments made to the Compassionate Use Advisory Board under G.S. 90-113.113 shall be made not later than 45 days after the effective date of this act. In order to provide for the staggering of terms, the initial term for each member appointed under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)i. shall be two years. Members appointed pursuant to G.S. 90-113.113(a)(1)g. and (a)(1)h. prior to the issuance of identification cards shall represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis and a parent of a minor qualified patient with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1)i. prior to the licensing of suppliers shall be a prospective supplier. In order to allow for the staggering of terms, the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)c., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(2) and (a)(3) shall be one year. Subsequent appointments shall be for the full four-year term in accordance with G.S. 90-113.113(b). SECTION 2.(b) The initial appointments made to the Medical Cannabis Production Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date of this act, and the Commission must hold their first meeting not later than 60 days after the effective date of this act. Within 270 days of the first meeting, the Commission must adopt rules, as required by G.S. 90-113.118(k), and establish the medical		-	• • •	ons of this Article
 Board under G.S. 90-113.113 shall be made not later than 45 days after the effective date of this act. In order to provide for the staggering of terms, the initial term for each member appointed under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)i. shall be two years. Members appointed pursuant to G.S. 90-113.113(a)(1)g. and (a)(1)h. prior to the issuance of identification cards shall represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis and a parent of a minor qualified patient with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1)i. prior to the licensing of suppliers shall be a prospective supplier. In order to allow for the staggering of terms, the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)a., (a)(1)c., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(2) and (a)(3) shall be one year. Subsequent appointments shall be for the full four-year term in accordance with G.S. 90-113.113(b). SECTION 2.(b) The initial appointments made to the Medical Cannabis Production Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date of this act, and the Commission must hold their first meeting not later than 60 days after the effective date of this act. Within 270 days of the first meeting, the Commission must adopt rules, as required by G.S. 90-113.118(k), and establish the medical cannabis supply system, as required 				noto Ilao Adriana
 act. In order to provide for the staggering of terms, the initial term for each member appointed under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)i. shall be two years. Members appointed pursuant to G.S. 90-113.113(a)(1)g. and (a)(1)h. prior to the issuance of identification cards shall represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis and a parent of a minor qualified patient with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1)i. prior to the licensing of suppliers shall be a prospective supplier. In order to allow for the staggering of terms, the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)a., (a)(1)c., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(b). SECTION 2.(b) The initial appointments made to the Medical Cannabis Production Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date of this act, and the Commission must hold their first meeting not later than 60 days after the effective date of this act. Within 270 days of the first meeting, the Commission must adopt rules, as required by G.S. 90-113.118(k), and establish the medical cannabis supply system, as required 			· · · · ·	•
 under G.S. 90-113.113(a)(1)g., (a)(1)h., and (a)(1)i. shall be two years. Members appointed pursuant to G.S. 90-113.113(a)(1)g. and (a)(1)h. prior to the issuance of identification cards shall represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis and a parent of a minor qualified patient with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1)i. prior to the licensing of suppliers shall be a prospective supplier. In order to allow for the staggering of terms, the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)a., (a)(1)c., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(2) and (a)(3) shall be one year. Subsequent appointments shall be for the full four-year term in accordance with G.S. 90-113.113(b). SECTION 2.(b) The initial appointments made to the Medical Cannabis Production Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date of this act, and the Commission must hold their first meeting not later than 60 days after the effective date of this act. Within 270 days of the first meeting, the Commission must adopt rules, as required by G.S. 90-113.118(k), and establish the medical cannabis supply system, as required 				
 pursuant to G.S. 90-113.113(a)(1)g. and (a)(1)h. prior to the issuance of identification cards shall represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis and a parent of a minor qualified patient with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1)i. prior to the licensing of suppliers shall be a prospective supplier. In order to allow for the staggering of terms, the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)a., (a)(1)c., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(2) and (a)(3) shall be one year. Subsequent appointments shall be for the full four-year term in accordance with G.S. 90-113.113(b). SECTION 2.(b) The initial appointments made to the Medical Cannabis Production Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date of this act, and the Commission must hold their first meeting not later than 60 days after the effective date of this act. Within 270 days of the first meeting, the Commission must adopt rules, as required by G.S. 90-113.118(k), and establish the medical cannabis supply system, as required 		-		
 represent a potential registry identification cardholder with a debilitating medical condition who intends to use cannabis and a parent of a minor qualified patient with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1)i. prior to the licensing of suppliers shall be a prospective supplier. In order to allow for the staggering of terms, the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)a., (a)(1)c., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(2) and (a)(3) shall be one year. Subsequent appointments shall be for the full four-year term in accordance with G.S. 90-113.113(b). SECTION 2.(b) The initial appointments made to the Medical Cannabis Production Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date of this act, and the Commission must hold their first meeting not later than 60 days after the effective date of this act. Within 270 days of the first meeting, the Commission must adopt rules, as required by G.S. 90-113.118(k), and establish the medical cannabis supply system, as required 				11
 intends to use cannabis and a parent of a minor qualified patient with a debilitating medical condition who intends to use cannabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1)i. prior to the licensing of suppliers shall be a prospective supplier. In order to allow for the staggering of terms, the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)a., (a)(1)c., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(2) and (a)(3) shall be one year. Subsequent appointments shall be for the full four-year term in accordance with G.S. 90-113.113(b). SECTION 2.(b) The initial appointments made to the Medical Cannabis Production Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date of this act, and the Commission must hold their first meeting not later than 60 days after the effective date of this act. Within 270 days of the first meeting, the Commission must adopt rules, as required by G.S. 90-113.118(k), and establish the medical cannabis supply system, as required 				
 condition who intends to use canabis. A representative of a licensed supplier appointed pursuant to G.S. 90-113.113(a)(1)i. prior to the licensing of suppliers shall be a prospective supplier. In order to allow for the staggering of terms, the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)a., (a)(1)c., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(2) and (a)(3) shall be one year. Subsequent appointments shall be for the full four-year term in accordance with G.S. 90-113.113(b). SECTION 2.(b) The initial appointments made to the Medical Cannabis Production Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date of this act, and the Commission must hold their first meeting not later than 60 days after the effective date of this act. Within 270 days of the first meeting, the Commission must adopt rules, as required by G.S. 90-113.118(k), and establish the medical cannabis supply system, as required 			· ·	
 to G.S. 90-113.113(a)(1)i. prior to the licensing of suppliers shall be a prospective supplier. In order to allow for the staggering of terms, the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)a., (a)(1)c., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(2) and (a)(3) shall be one year. Subsequent appointments shall be for the full four-year term in accordance with G.S. 90-113.113(b). SECTION 2.(b) The initial appointments made to the Medical Cannabis Production Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date of this act, and the Commission must hold their first meeting not later than 60 days after the effective date of this act. Within 270 days of the first meeting, the Commission must adopt rules, as required by G.S. 90-113.118(k), and establish the medical cannabis supply system, as required 				-
 order to allow for the staggering of terms, the initial term for each member appointed pursuant to G.S. 90-113.113(a)(1)a., (a)(1)c., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(2) and (a)(3) shall be one year. Subsequent appointments shall be for the full four-year term in accordance with G.S. 90-113.113(b). SECTION 2.(b) The initial appointments made to the Medical Cannabis Production Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date of this act, and the Commission must hold their first meeting not later than 60 days after the effective date of this act. Within 270 days of the first meeting, the Commission must adopt rules, as required by G.S. 90-113.118(k), and establish the medical cannabis supply system, as required 				
 to G.S. 90-113.113(a)(1)a., (a)(1)c., and (a)(1)d. shall be four years; for each member appointed pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(2) and (a)(3) shall be one year. Subsequent appointments shall be for the full four-year term in accordance with G.S. 90-113.113(b). SECTION 2.(b) The initial appointments made to the Medical Cannabis Production Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date of this act, and the Commission must hold their first meeting not later than 60 days after the effective date of this act. Within 270 days of the first meeting, the Commission must adopt rules, as required by G.S. 90-113.118(k), and establish the medical cannabis supply system, as required 				
 pursuant to G.S. 90-113.113(a)(1)b., (a)(1)e., and (a)(1)f., the initial term shall be three years; and the initial term for members appointed pursuant to G.S. 90-113.113(a)(2) and (a)(3) shall be one year. Subsequent appointments shall be for the full four-year term in accordance with G.S. 90-113.113(b). SECTION 2.(b) The initial appointments made to the Medical Cannabis Production Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date of this act, and the Commission must hold their first meeting not later than 60 days after the effective date of this act. Within 270 days of the first meeting, the Commission must adopt rules, as required by G.S. 90-113.118(k), and establish the medical cannabis supply system, as required 				
 and the initial term for members appointed pursuant to G.S. 90-113.113(a)(2) and (a)(3) shall be one year. Subsequent appointments shall be for the full four-year term in accordance with G.S. 90-113.113(b). SECTION 2.(b) The initial appointments made to the Medical Cannabis Production Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date of this act, and the Commission must hold their first meeting not later than 60 days after the effective date of this act. Within 270 days of the first meeting, the Commission must adopt rules, as required by G.S. 90-113.118(k), and establish the medical cannabis supply system, as required 				
 one year. Subsequent appointments shall be for the full four-year term in accordance with G.S. 90-113.113(b). SECTION 2.(b) The initial appointments made to the Medical Cannabis Production Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date of this act, and the Commission must hold their first meeting not later than 60 days after the effective date of this act. Within 270 days of the first meeting, the Commission must adopt rules, as required by G.S. 90-113.118(k), and establish the medical cannabis supply system, as required 		-		•
 G.S. 90-113.113(b). SECTION 2.(b) The initial appointments made to the Medical Cannabis Production Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date of this act, and the Commission must hold their first meeting not later than 60 days after the effective date of this act. Within 270 days of the first meeting, the Commission must adopt rules, as required by G.S. 90-113.118(k), and establish the medical cannabis supply system, as required 				
46 SECTION 2.(b) The initial appointments made to the Medical Cannabis Production 47 Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date 48 of this act, and the Commission must hold their first meeting not later than 60 days after the 49 effective date of this act. Within 270 days of the first meeting, the Commission must adopt rules, 50 as required by G.S. 90-113.118(k), and establish the medical cannabis supply system, as required		-		
 Commission under G.S. 90-113.118 shall be made not later than 45 days after the effective date of this act, and the Commission must hold their first meeting not later than 60 days after the effective date of this act. Within 270 days of the first meeting, the Commission must adopt rules, as required by G.S. 90-113.118(k), and establish the medical cannabis supply system, as required 				unnabis Production
 of this act, and the Commission must hold their first meeting not later than 60 days after the effective date of this act. Within 270 days of the first meeting, the Commission must adopt rules, as required by G.S. 90-113.118(k), and establish the medical cannabis supply system, as required 				
 effective date of this act. Within 270 days of the first meeting, the Commission must adopt rules, as required by G.S. 90-113.118(k), and establish the medical cannabis supply system, as required 				
50 as required by G.S. 90-113.118(k), and establish the medical cannabis supply system, as required	49			
51 by G.S. 90-113.119. In order to provide for the staggering of terms, the initial term for each	50			1
	51	by G.S. 90-113.1	19. In order to provide for the staggering of terms, the init	itial term for each

General Assembly Of North Carolina

2 for members appointed pursuant to G.S. 90-113.118(3) through (9) shall be two years. The initial term for members appointed pursuant to G.S. 90-113.118(5) through (6) shall be four years. 5 Subsequent appointments shall be for the full four-year term in accordance with G.S. 90-113.118(b). 7 SECTION 2.(c) Within 270 days of the effective date of this act, the North Carolina 8 Medical Care Commission must adopt rules as required by G.S. 90-113.115(b). 9 SECTION 2.(d) No later than 30 days after the effective date of this act, the North Carolina Medical Board shall approve a three-hour continuing medical education course on cannabis and cannabis-infused products. 9 SECTION 3. G.S. 105-164.13 reads as rewritten: 7 § 105-164.13. Retail sales and use tax. The sale at retail and the use, storage, or consumption in this State of the following items are specifically exempted from the tax imposed by this Article: 10 (13e) Cannabis or cannabis-infused products sold by a medical cannabis center to a registry identification cardholder. The terms "cannabis." "cannabis-infused product." "medical cannabis center," and "registry identification cardholder" have the same meanings as defined in G.S. 90-113.112. 11 (13e) Cannabis or cannabis and servirten: "* 12 the tax imposed by this Article: 13 (13e) Cannabis or cannabis as rewritten: "* 14 (14) T	1	11	ed under G.S. 90-113.118(a)(1)a. and (a)(7) shall be one year. The initial term
 term for members appointed pursuant to G.S. 90-113.118(5) through (6) shall be four years. Subsequent appointments shall be for the full four-year term in accordance with G.S. 90-113.118(b). SECTION 2.(c) Within 270 days of the effective date of this act, the North Carolina Medical Care Commission must adopt rules as required by G.S. 90-113.115(h). SECTION 2.(d) No later than 30 days after the effective date of this act, the North Carolina Medical Board shall approve a three-hour continuing medical education course and a one-hour supplemental medical education course on cannabis and cannabis-infused products. SECTION 3. G.S. 105-164.13 reads as rewritten: "\$ 105-164.13. Retail sales and use tax. The sale at retail and the use, storage, or consumption in this State of the following items are specifically exempted from the tax imposed by this Article: (13e) Cannabis or cannabis-infused products sold by a medical cannabis-infused product, "medical cannabis cantern," and "registry identification cardholder." have the same meanings as defined in G.S. 90-113.112. SECTION 4. G.S. 106-121 reads as rewritten: "\$ 106-121. Definitions and general consideration. For the purpose of this Article: " (6) The term "drug" means all of the following: a. Articles recognized in the official United States Pharmacopoeia, official Homeopathic of the disease in man or other aminals; andanimals, except for cannabis or cannabis or cannabis-infused products, as defined in G.S. 90-113.112. C. Articles (other than food) intended to affect the structure or any function of the body of man or other aminals; andanimals, except for cannabis or cannabis or cannabis-infused products, as defined in G.S. 90-113.112. C. Articles used for food or drink for man or other animals, andanimals, except for cannabis or cannabis or cannabis infused products, as defined in G.S.	2	**	1
 Subsequent appointments shall be for the full four-year term in accordance with G.S. 90-113.118(b). SECTION 2.(c) Within 270 days of the effective date of this act, the North Carolina Medical Care Commission must adopt rules as required by G.S. 90-113.115(b). SECTION 2.(d) No later than 30 days after the effective date of this act, the North Carolina Medical Board shall approve a three-hour continuing medical education course and a one-hour supplemental medical education course on cannabis and cannabis-infused products. SECTION 3. G.S. 105-164.13 reads as rewritten: "\$ 105-164.13. Retail sales and use tax. The sale at retail and the use, storage, or consumption in this State of the following items are specifically exempted from the tax imposed by this Article: (12e) Cannabis or cannabis-infused products sold by a medical cannabis center to a registry identification cardholder. The terms "cannabis." "cannabis."infused product," "medical cannabis center," and "registry identification cardholder." have the same meanings as defined in G.S. 90-113.112. SECTION 4. G.S. 106-121 reads as rewritten: "\$ 106-121. Definitions and general consideration. For the purpose of this Article: " G(6) The term "drug" means all of the following: a. Articles recognized in the official United States. Pharmacopoeia, official Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them: andthem. b. Articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or other animals; andgninals, except for cannabis or cannabis-infused products, as defined in G.S. 90-113.112. C. Articles intended for use as a component of any article specified in paragraphs a, b or c; but does not include devices or their components, paragraphs a, b or c; but does not include			
 G.S. 90-113.118(b). SECTION 2.(c) Within 270 days of the effective date of this act, the North Carolina Medical Care Commission must adopt rules as required by G.S. 90-113.115(h). SECTION 2.(d) No later than 30 days after the effective date of this act, the North Carolina Medical Board shall approve a three-hour continuing medical education course and a one-hour supplemental medical education course on cannabis and cannabis-infused products. SECTION 3. G.S. 105-164.13 reads as rewritten: "§ 105-164.13. Retail sales and use tax. The sale at retail and the use, storage, or consumption in this State of the following items are specifically exempted from the tax imposed by this Article: 			
7 SECTION 2.(c) Within 270 days of the effective date of this act, the North Carolina 8 Medical Care Commission must adopt rules as required by G.S. 90-113.115(h). 9 SECTION 3.(d) No later than 30 days after the effective date of this act, the North 10 one-hour supplemental medical education course on cannabis and cannabis-infused products. 11 SECTION 3. G.S. 105-164.13 reads as rewritten: 12 SECTION 3. G.S. 105-164.13 reads as rewritten: 13 "\$ 105-164.13. Retail sales and use tax. 14 The sale at retail and the use, storage, or consumption in this State of the following items are specifically exempted from the tax imposed by this Article: 16 17 (13e) Cannabis or cannabis-infused products sold by a medical cannabis enter to a registry identification cardholder. The terms "cannabis," "cannabis.infused product," "medical cannabis center," and "registry identification cardholder." 18 registry identification cardholder. The terms "cannabis," "cannabis." 19 product," "medical cannabis center," and "registry identification cardholder." 10 have the same meanings as defined in G.S. 90-113.112. 11 12 SECTION 4. G.S. 106-121 reads as rewritten: 13 106-121. Definitions and general consideration.			•
8 Medical Care Commission must adopt rules as required by G.S. 90-113.115(h). 9 SECTION 2.(d) No later than 30 days after the effective date of this act, the North 1 Carolina Medical Board shall approve a three-hour continuing medical education course and a 11 one-hour supplemental medical education course on cannabis and cannabis-infused products. 12 SECTION 3. G.S. 105-164.13 reads as rewritten: 13 The sale at retail and the use, storage, or consumption in this State of the following items are specifically exempted from the tax imposed by this Article: 14 The sale at retail and the use, storage, or consumption in this State of the following items are specifically exempted from the tax imposed by this Article: 16 17 (13e) Cannabis or cannabis-infused products sold by a medical cannabis center: and "registry identification cardholder" have the same meanings as defined in G.S. 90-113.112. 17 maxe the same meanings as defined in G.S. 90-113.112. 18 SECTION 4. G.S. 106-121 reads as rewritten: 19 product," "medical cannabis center," and "registry identification cardholder" have the same meanings as defined in G.S. 90-113.112. 19 20 (6) The term "drug" means all of the following: 10 a. Articles recognized in the officia		G.S. 90-113.118(b).
9 SECTION 2.(d) No later than 30 days after the effective date of this act, the North 10 Carolina Medical Board shall approve a three-hour continuing medical education course and a 11 one-hour supplemental medical education course on cannabis and cannabis-infused products. 12 SECTION 3. G.S. 105-164.13 reads as rewritten: 13 "\$ 105-164.13. Retail sales and use tax. 14 The sale at retail and the use, storage, or consumption in this State of the following items are specifically exempted from the tax imposed by this Article: 16 (13e) Cannabis or cannabis-infused products sold by a medical cannabis center to a registry identification cardholder. The terms "cannabis." "cannabis.infused product," "medical cannabis center," and "registry identification cardholder." 17 May the same meanings as defined in G.S. 90-113.112. 18 " 29 bave the same meanings as defined in G.S. 90-113.112. 19 " 20 have the same meanings as defined in G.S. 90-113.112. 21 " 22 " 23 106-121. Definitions and general consideration. 24 " 25 26 (6) The term "drug" means all of the following: 3.	7	SECT	TON 2.(c) Within 270 days of the effective date of this act, the North Carolina
10 Carolina Medical Board shall approve a three-hour continuing medical education course and a one-hour supplemental medical education course on cannabis and cannabis-infused products. SECTION 3. G.S. 105-164.13 reads as rewritten: 11 "\$ 105-164.13. Retail sales and use tax. 12 The sale at retail and the use, storage, or consumption in this State of the following items are specifically exempted from the tax imposed by this Article: 13 "(13e) Cannabis or cannabis-infused products sold by a medical cannabis center to a registry identification cardholder. The terms "cannabis." "cannabis-infused product," "medical cannabis center," and "registry identification cardholder," have the same meanings as defined in G.S. 90-113.112. 14 SECTION 4. G.S. 106-121 reads. 17 (6) The term "drug" means all of the following: 18 " 19 product," "medical roundary, or any supplement to any of them; andthem. 19 " 10 (6) The term "drug" means all of the following: 10 a. Articles recognized in the diagnosis, cure, mitigation, treatment or prevention of disease in man or other animals; andanimals, except for cannabis or cannabis or cannabis-infused products, as defined in G.S. 90-113.112. 10 b. Articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or other animals; andanimals, except for cannabis or cannabis-infused products, as defi	8	Medical Care Con	mmission must adopt rules as required by G.S. 90-113.115(h).
11 one-hour supplemental medical education course on cannabis and cannabis-infused products. 12 SECTION 3. G.S. 105-164.13 reads as rewritten: 13 "\$ 105-164.13. Read and use tax. 14 The sale at retail and the use, storage, or consumption in this State of the following items are specifically exempted from the tax imposed by this Article: 16 (13e) Cannabis or cannabis-infused products sold by a medical cannabis center to a registry identification cardholder. The terms "cannabis," "cannabis.infused product," "medical cannabis center," and "registry identification cardholder" have the same meanings as defined in G.S. 90-113.112. 17 have the same meanings as defined in G.S. 90-113.112. 18 "s 106-121. Definitions and general consideration. 19 For the purpose of this Article: 10 11 G.O. The term "drug" means all of the following: 12 a. Articles recognized in the official United States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United States, or official 12 National Formulary, or any supplement to any of them; and them, or prevention of disease in man or other animals; andanimals, except for cannabis or cannabis-infused product, as defined in G.S. 90-113.112. 12 for cannabis or cannabis center, as defined in G.S. 90-113.112. 13 G.O. Articles (other than food) intended to affect the structure or any function of the bo	9	SECT	`ION 2.(d) No later than 30 days after the effective date of this act, the North
12 SECTION 3. G.S. 105-164.13 reads as rewritten: 13 "\$ 105-164.13. Retail sales and use tax. 14 The sale at retail and the use, storage, or consumption in this State of the following items are specifically exempted from the tax imposed by this Article: 16 (13e) Cannabis or cannabis-infused products sold by a medical cannabis center to a registry identification cardholder. The terms "cannabis." "cannabis-infused product," "medical cannabis center," and "registry identification cardholder" have the same meanings as defined in G.S. 90-113.112. 17 SECTION 4. G.S. 106-121 reads as rewritten: 18 "s 106-121. Definitions and general consideration. 19 product," "medical cannabis center," and "registry identification cardholder" have the same meanings as all of the following: 20 (6) The term "drug" means all of the following: 21 " 22 (6) The term "drug" means all of the following: 23 " 24 (6) The term "drug" means all of the following: 26 (6) The term "drug" means all of the following: 27 a. Articles 28 official Homeopathic Pharmacopoeia of the United States, or official 29 National Formulary, or any supplement to any of thems; andgnimals, except </td <td>10</td> <td>Carolina Medical</td> <td>Board shall approve a three-hour continuing medical education course and a</td>	10	Carolina Medical	Board shall approve a three-hour continuing medical education course and a
 "\$ 105-164.13. Retail sales and use tax. The sale at retail and the use, storage, or consumption in this State of the following items are specifically exempted from the tax imposed by this Article: (13e) Cannabis or cannabis-infused products sold by a medical cannabis center to a registry identification cardholder. The terms "cannabis," "cannabis.' "cannabis.' "cannabis' " product," "medical cannabis center," and "registry identification cardholder" have the same meanings as defined in G.S. 90-113.112. SECTION 4. G.S. 106-121 reads as rewritten: "\$ 106-121. Definitions and general consideration. For the purpose of this Article: " (6) The term "drug" means all of the following: a. Articles recognized in the official United States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; andthem. b. Articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or other animak; andanimals, except for cannabis: or cannabis-infused products, as defined in G.S. 90-113.112. C. Articles (other than food) intended to affect the structure or any function of the body of man or other animak; andgnimals, c. Articles intended for use as a component of any article specified in paragraphs a, b or c; but does not include devices or their components, parts, or accessories. (8) The term "food" means all of the following: a. Articles used for food or drink for man or other animals, except for cannabis center, as defined in G.S. 90-113.112. that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. (7) C. Articles used for food or drink for man or other animals, except for cannabis center, as defined in G.S. 90-113.112. (8) The term "food" means all of the following: <li< td=""><td>11</td><td>one-hour supplem</td><td>nental medical education course on cannabis and cannabis-infused products.</td></li<>	11	one-hour supplem	nental medical education course on cannabis and cannabis-infused products.
14 The sale at retail and the use, storage, or consumption in this State of the following items are specifically exempted from the tax imposed by this Article: 15 specifically exempted from the tax imposed by this Article: 16 (13e) Cannabis or cannabis-infused products sold by a medical cannabis center to a registry identification cardholder. The terms "cannabis." "cannabis-infused product." "medical cannabis center," and "registry identification cardholder" have the same meanings as defined in G.S. 90-113.112. 17 SECTION 4. G.S. 106-121 reads as rewritten: 18 secore of the structure of the following: 20 " 21 " 22 SECTION 4. G.S. 106-121 reads as rewritten: 23 SECTION 4. G.S. 106-121 reads as rewritten: 24 for the purpose of this Article: 25 26 (6) 27 a. 28 Articles recognized in the official United States or official National Formulary, or any supplement to any of them; andthem. 30 b. Articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or other animals; and_animals, except for cannabis or cannabis center, as defined in G.S. 90-113.112. 31 G.S. 90-113.114, that are manufactured by a productis or their components, parts, or accessories. <	12	SECT	TON 3. G.S. 105-164.13 reads as rewritten:
 specifically exempted from the tax imposed by this Article: (13e) Cannabis or cannabis-infuged products sold by a medical cannabis center to a registry identification cardholder. The terms "cannabis," "cannabis-infuged product," "medical cannabis center," and "registry identification cardholder" have the same meanings as defined in G.S. 90-113.112. " SECTION 4. G.S. 106-121 reads as rewritten: "\$ 106-121. Definitions and general consideration. For the purpose of this Article: " G(6) The term "drug" means all of the following: a. Articles recognized in the official United States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; andthem. b. Articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or other animals; andanimals, except for cannabis infused products as defined in G.S. 90-113.112. C. Articles (other than food) intended to affect the structure or any function of the body of man or other animals; andanimals. c. Articles intended for use as a component of any article specified in paragraphs a, b or c; but does not include devices or their components, parts, or accessories. (8) The term "food" means all of the following: a. Articles used for food or drink for man or other animals. except for cannabis center, as defined in G.S. 90-113.112, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112, that are manufacture	13	"§ 105-164.13. R	Retail sales and use tax.
16 17 (13e) Cannabis or cannabis-infused products sold by a medical cannabis center to a registry identification cardholder. The terms "cannabis," "cannabis-infused product," "medical cannabis center," and "registry identification cardholder" have the same meanings as defined in G.S. 90-113.112. 18 " 20 have the same meanings as defined in G.S. 90-113.112. 21 " 22 SECTION 4. G.S. 106-121 reads as rewritten: 23 SECTION 5. 106-121 reads as rewritten: 24 National general consideration. 25 " 26 (6) The term "drug" means all of the following: 27 a. Articles recognized in the official United States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; andmethem or prevention of disease in man or other animals; andmimals, except for cannabis center, as defined in G.S. 90-113.112. 30 b. Articles intended for use as a component of any article specified in G.S. 90-113.112. 31 G.S. 90-113.114, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. 35 c. Articles intended for use as a component of any article specified in paragraphs a, b or c; but does not include devices or their components, parts, or accessories. <	14	The sale at ref	tail and the use, storage, or consumption in this State of the following items are
16 17 (13e) Cannabis or cannabis-infused products sold by a medical cannabis center to a registry identification cardholder. The terms "cannabis," "cannabis-infused product," "medical cannabis center," and "registry identification cardholder" have the same meanings as defined in G.S. 90-113.112. 18 " 20 have the same meanings as defined in G.S. 90-113.112. 21 " 22 SECTION 4. G.S. 106-121 reads as rewritten: 23 SECTION 5. 106-121 reads as rewritten: 24 National general consideration. 25 " 26 (6) The term "drug" means all of the following: 27 a. Articles recognized in the official United States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; andmethem or prevention of disease in man or other animals; andmimals, except for cannabis center, as defined in G.S. 90-113.112. 30 b. Articles intended for use as a component of any article specified in G.S. 90-113.112. 31 G.S. 90-113.114, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. 35 c. Articles intended for use as a component of any article specified in paragraphs a, b or c; but does not include devices or their components, parts, or accessories. <	15		• •
18 registry identification cardholder. The terms "cannabis." "cannabis.infused product," "medical cannabis center," and "registry identification cardholder" have the same meanings as defined in G.S. 90-113.112. 20 have the same meanings as defined in G.S. 90-113.112. 21 " 22 SECTION 4. G.S. 106-121 reads as rewritten: 23 "\$ 106-121. Definitions and general consideration. 24 For the purpose of this Article: 25 26 (6) 27 a. 28 Articles recognized in the official United States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; andthem. 30 b. 31 G.S. 90-113.114, that are manufactured by a products, as defined in G.S. 90-113.112. 32 for cannabis or cannabis-infused products, as defined in G.S. 90-113.112. 34 by a medical cannabis center, as defined in G.S. 90-113.112. 35 c. Articles (other than food) intended to affect the structure or any function of the body of man or other animals; andanimals. 37 d. Articles used for food or drink for man or other animals, except for cannabis or cannabis-infused products, as defined in G.S. 90-113.112. 36 The term "food" means all of the foll	16	· ·	· · · ·
18 registry identification cardholder. The terms "cannabis." "cannabis.infused product," "medical cannabis center," and "registry identification cardholder" have the same meanings as defined in G.S. 90-113.112. 20 have the same meanings as defined in G.S. 90-113.112. 21 " 22 SECTION 4. G.S. 106-121 reads as rewritten: 23 "\$ 106-121. Definitions and general consideration. 24 For the purpose of this Article: 25 26 (6) 27 a. 28 Articles recognized in the official United States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; andthem. 30 b. 31 G.S. 90-113.114, that are manufactured by a products, as defined in G.S. 90-113.112. 32 for cannabis or cannabis-infused products, as defined in G.S. 90-113.112. 34 by a medical cannabis center, as defined in G.S. 90-113.112. 35 c. Articles (other than food) intended to affect the structure or any function of the body of man or other animals; andanimals. 37 d. Articles used for food or drink for man or other animals, except for cannabis or cannabis-infused products, as defined in G.S. 90-113.112. 36 The term "food" means all of the foll	17	(13e)	Cannabis or cannabis-infused products sold by a medical cannabis center to a
19 product," "medical cannabis center," and "registry identification cardholder" 20 have the same meanings as defined in G.S. 90-113.112. 21 " 22 SECTION 4. G.S. 106-121 reads as rewritten: 23 "§ 106-121. Definitions and general consideration. 24 For the purpose of this Article: 25 26 (6) 27 a. Articles recognized in the official United States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; andthem. 30 b. Articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or other animals; andanimals, except for cannabis or cannabis -infused products, as defined in G.S. 90-113.112. 33 G.S. 90-113.114, that are manufactured by a production facility or sold by a medical cannabis center, as defined to affect the structure or any function of the body of man or other animals; andanimals. 37 d. Articles intended for use as a component of any article specified in paragraphs a, b or c; but does not include devices or their components, parts, or accessories. 39 41 (8) 42 a. Articles used for food or drink for man or other animals, <u>except for cannabis center, as defined in G.S. 90-113.112</u> , that are manufactured by a production facility or sold by a medical cannab	18		
20 have the same meanings as defined in G.S. 90-113.112. 21 " 22 SECTION 4. G.S. 106-121 reads as rewritten: 23 "\$ 106-121. Definitions and general consideration. 24 For the purpose of this Article: 25 26 (6) 27 a. 28 official Homeopathic Pharmacopoeia of the United States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; andthem. 30 b. 31 Articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or other animals; andanimals, except for cannabis or cannabis-infused products, as defined in G.S. 90-113.112. 31 G.S. 90-113.114, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. 35 c. 36 Articles (other than food) intended to affect the structure or any function of the body of man or other animals; andanimals. 37 d. 40 Articles intended for use as a component of any article specified in paragraphs a, b or c; but does not include devices or their components, paragraphs a, b or c; but does not include devices or their components, paragraphs a, b or c; but does not include devices or their cannabis or cannabis-infused products, as defined in G.S. 9			
21 " 22 SECTION 4. G.S. 106-121 reads as rewritten: 23 "§ 106-121. Definitions and general consideration. 24 For the purpose of this Article: 25 26 (6) 27 a. 28 official Homeopathic Pharmacopoeia of the United States Pharmacopoeia, official Momeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; and(them, and them, or prevention of disease in man or other animals; and, animals, except for cannabis or cannabis-infused products, as defined in G.S. 90-113.114, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. 36 c. 37 d. 38 or cicles (other than food) intended to affect the structure or any function of the body of man or other animals; and, animals. 37 d. 38 articles intended for use as a component of any article specified in paragraphs a, b or c; but does not include devices or their components, parts, or accessories. 39 41 (8) 42 a. 44 the term "food" means all of the following: 45 46 47 d.			
 SECTION 4. G.S. 106-121 reads as rewritten: "\$ 106-121. Definitions and general consideration. For the purpose of this Article: (6) The term "drug" means all of the following: a. Articles recognized in the official United States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; and(them.) b. Articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or other animals; andanimals, except for cannabis-infused products, as defined in G.S. 90-113.114, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. c. Articles (other than food) intended to affect the structure or any function of the body of man or other animals; andanimals. (8) The term "food" means all of the following: a. Articles used for food or drink for man or other animals, except for cannabis or cannabis-infused products, as defined in paragraphs a, b or c; but does not include devices or their components, parts, or accessories. (8) The term "food" means all of the following: a. Articles used for food or drink for man or other animals, except for cannabis or cannabis-infused products, as defined in G.S. 90-113.112. (7) that are manufactured by a production facility or sold by a medical cannabis or cannabis-infused products, as defined in G.S. 90-113.112. (8) The term "food" means all of the following: (9) Chewing gum, andgum. (10) Chewing gum, andgum. (11) Chewing gum, andgum. (2) Articles used for components of any such article. (3) The term "food" cannabis-infused products, as defined in G.S. 90-113.112. 			
 ¹§ 106-121. Definitions and general consideration. For the purpose of this Article: (6) The term "drug" means <u>all of the following:</u> a. Articles recognized in the official United States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; and them. b. Articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or other animals; andanimals, except for cannabis or cannabis-infused products, as defined in G.S. 90-113.114, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. c. Articles (other than food) intended to affect the structure or any function of the body of man or other animals; andanimals. d. Articles intended for use as a component of any article specified in paragraphs a, b or c; but does not include devices or their components, parts, or accessories. (8) The term "food" means <u>all of the following:</u> a. Articles used for food or drink for man or other animals, <u>except for cannabis center</u>, as defined in G.S. 90-113.112, that are manufactured by a production facility or sold by a matice specified. 		SECT	ION 4. G.S. 106-121 reads as rewritten:
 For the purpose of this Article: (6) The term "drug" means <u>all of the following:</u> a. Articles recognized in the official United States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; andthem. b. Articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or other animals; andanimals, except for cannabis or cannabis-infused products, as defined in G.S. 90-113.114, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. c. Articles (other than food) intended to affect the structure or any function of the body of man or other animals; andanimals. d. Articles intended for use as a component of any article specified in paragraphs a, b or c; but does not include devices or their components, parts, or accessories. (8) The term "food" means <u>all of the following:</u> a. Articles used for food or drink for man or other animals, <u>except for cannabis or cannabis-infused products, as defined in G.S. 90-113.112</u>, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. c. Articles used for food or drink for man or other animals, <u>except for cannabis center, as defined in G.S. 90-113.112</u>, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. b. Chewing gum, andgum. c. Articles used for components of any such article. " SECTION 4.5.(a) G.S. 15A-974 reads as rewritten: "§ 15A-974. Exclusion or suppression of unlawfully obtained evidence. 			
 25 26 (6) The term "drug" means <u>all of the following:</u> a. Articles recognized in the official United States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; andthem. 30 b. Articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or other animals; andanimals, except for cannabis or cannabis-infused products, as defined in 33 G.S. 90-113.114, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. 35 c. Articles (other than food) intended to affect the structure or any function of the body of man or other animals; andanimals. 37 d. Articles intended for use as a component of any article specified in paragraphs a, b or c; but does not include devices or their components, parts, or accessories. 41 (8) The term "food" means <u>all of the following:</u> a. Articles used for food or drink for man or other animals, <u>except for cannabis or cannabis-infused products, as defined in G.S. 90-113.112</u>. that are manufactured by a production facility or sold by a medical cannabis or cannabis-infused products, as defined in G.S. 90-113.112. that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. that are manufactured by a product as defined in G.S. 90-113.112. that are manufactured by a product as a defined in G.S. 90-113.112. that are manufactured by a product as a defined in G.S. 90-113.112. that are manufactured by a product as a defined in G.S. 90-113.112. that are manufactured by a product as a defined in G.S. 90-113.112. that are manufactured by a product as a defined in G.S. 90-113.112. that are m			
26 (6) The term "drug" means all of the following: 27 a. Articles recognized in the official United States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; andthem. 30 b. Articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or other animals; andanimals, except for cannabis or cannabis-infused products, as defined in G.S. 90-113.114, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. 31 G.S. 90-113.114, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. 35 c. Articles (other than food) intended to affect the structure or any function of the body of man or other animals; andanimals. 37 d. Articles intended for use as a component of any article specified in paragraphs a, b or c; but does not include devices or their components, parts, or accessories. 40 41 (8) The term "food" means all of the following: 42 a. Articles used for food or drink for man or other animals, except for cannabis or cannabis-infused products, as defined in G.S. 90-113.112. 44 b. Chewing gum, andgum. 47 c. Articles used for components of any such article. 48 " 49 SECTION 4.5.(a) G.S. 15A-974 reads as rewritten: 50<		1 I 	
 a. Articles recognized in the official United States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; andthem. b. Articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or other animals; andanimals, except for cannabis or cannabis-infused products, as defined in G.S. 90-113.114, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. c. Articles (other than food) intended to affect the structure or any function of the body of man or other animals; andanimals. d. Articles intended for use as a component of any article specified in paragraphs a, b or c; but does not include devices or their components, parts, or accessories. (8) The term "food" means all of the following: a. Articles used for food or drink for man or other animals, except for cannabis center, as defined in G.S. 90-113.112, that are manufactured by a production facility or sold by a medical cannabis infused products, as defined in G.S. 90-113.112, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. b. Chewing gum, andgum. c. Articles used for components of any such article. " 		(6)	The term "drug" means all of the following:
28 official Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; andthem. 30 b. Articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or other animals; andanimals, except for cannabis or cannabis-infused products, as defined in G.S. 90-113.114, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. 33 G.S. 90-113.114, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. 35 c. 37 d. 38 paragraphs a, b or c; but does not include devices or their components, parts, or accessories. 40 41 (8) 42 a. 44 Articles used for food or drink for man or other animals, except for cannabis or cannabis-infused products, as defined in G.S. 90-113.112, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112, that are manufactured by a production facility or sold by a medical cannabis or cannabis-infused products, as defined in G.S. 90-113.112, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. 46 b. 47 c. 48 " 49 SECTION 4.5.(a) G.S. 15A-974 reads as rewritten:		~ /	
29National Formulary, or any supplement to any of them; andthem.30b.Articles intended for use in the diagnosis, cure, mitigation, treatment31or prevention of disease in man or other animals; andanimals, except32for cannabis or cannabis-infused products, as defined in33G.S. 90-113.114, that are manufactured by a production facility or sold34by a medical cannabis center, as defined in G.S. 90-113.112.35c.Articles (other than food) intended to affect the structure or any36function of the body of man or other animals; andanimals.37d.Articles intended for use as a component of any article specified in38paragraphs a, b or c; but does not include devices or their components,39paragraphs a, b or c; but does not include devices or their components,4041(8)The term "food" means all of the following:42a.Articles used for food or drink for man or other animals, except for43cannabis or cannabis-infused products, as defined in G.S. 90-113.112,44that are manufactured by a production facility or sold by a medical45cannabis or cannabis-infused products, as defined in G.S. 90-113.112,46b.Chewing gum, andgum.47c.48"49SECTION 4.5.(a) G.S. 15A-974 reads as rewritten:50"\$ 15A-974. Exclusion or suppression of unlawfully obtained evidence.			5
 b. Articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or other animals; andanimals, except for cannabis or cannabis-infused products, as defined in G.S. 90-113.114, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. c. Articles (other than food) intended to affect the structure or any function of the body of man or other animals; andanimals. d. Articles intended for use as a component of any article specified in paragraphs a, b or c; but does not include devices or their components, parts, or accessories. (8) The term "food" means all of the following: a. Articles used for food or drink for man or other animals, except for cannabis or cannabis-infused products, as defined in G.S. 90-113.112. that are manufactured by a production facility or sold by a medical cannabis or cannabis-infused products, as defined in G.S. 90-113.112. b. Chewing gum, andgum. c. Articles used for components of any such article. " SECTION 4.5.(a) G.S. 15A-974 reads as rewritten: * 15A-974. Exclusion or suppression of unlawfully obtained evidence. 			
31 or prevention of disease in man or other animals; andanimals, except 32 for cannabis or cannabis-infused products, as defined in 33 G.S. 90-113.114, that are manufactured by a production facility or sold 34 by a medical cannabis center, as defined in G.S. 90-113.112. 35 c. Articles (other than food) intended to affect the structure or any 36 function of the body of man or other animals; andanimals. 37 d. Articles intended for use as a component of any article specified in 38 paragraphs a, b or c; but does not include devices or their components, 39 paragraphs a, b or c; but does not include devices or their components, 39 paragraphs a, b or c; but does not include devices or their components, 39 paragraphs a, b or c; but does not include devices or their components, 39 paragraphs a, b or c; but does not include devices or their components, 39 paragraphs a, b or c; but does not include devices or their components, 41 (8) The term "food" means all of the following: 42 a. Articles used for food or drink for man or other animals, except for 43 cannabis center, as defined in G.S. 90-113.112. 44 that are manufactured by a production facility			J ['] J ['] II J ['] J [']
32for cannabis or cannabis-infused products, as defined in33G.S. 90-113.114, that are manufactured by a production facility or sold34by a medical cannabis center, as defined in G.S. 90-113.112.35c.Articles (other than food) intended to affect the structure or any36function of the body of man or other animals; andanimals.37d.Articles intended for use as a component of any article specified in38paragraphs a, b or c; but does not include devices or their components,39parts, or accessories.4041(8)The term "food" means all of the following:42a.43Articles used for food or drink for man or other animals, except for44cannabis or cannabis-infused products, as defined in G.S. 90-113.112,44that are manufactured by a production facility or sold by a medical45cannabis center, as defined in G.S. 90-113.112,46b.47c.48"49SECTION 4.5.(a)40G.S. 15A-974 reads as rewritten:50"§ 15A-974. Exclusion or suppression of unlawfully obtained evidence.			
33G.S. 90-113.114, that are manufactured by a production facility or sold34by a medical cannabis center, as defined in G.S. 90-113.112.35c. Articles (other than food) intended to affect the structure or any function of the body of man or other animals; andanimals.37d. Articles intended for use as a component of any article specified in paragraphs a, b or c; but does not include devices or their components, parts, or accessories.4041(8)The term "food" means all of the following: a. Articles used for food or drink for man or other animals, except for cannabis or cannabis-infused products, as defined in G.S. 90-113.112, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112.46b. Chewing gum, andgum. c. Articles used for components of any such article.47c. Articles used for components of any such article.48"49SECTION 4.5.(a) G.S. 15A-974 reads as rewritten:50"\$ 15A-974. Exclusion or suppression of unlawfully obtained evidence.			· · · · · · · · · · · · · · · · · · ·
34by a medical cannabis center, as defined in G.S. 90-113.112.35c. Articles (other than food) intended to affect the structure or any function of the body of man or other animals; andanimals.37d. Articles intended for use as a component of any article specified in paragraphs a, b or c; but does not include devices or their components, parts, or accessories.4041(8)The term "food" means all of the following: a. Articles used for food or drink for man or other animals, except for cannabis or cannabis-infused products, as defined in G.S. 90-113.112, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112.46b. Chewing gum, andgum. c. Articles used for components of any such article.47c. Articles used for components of any such article.48"49SECTION 4.5.(a) G.S. 15A-974 reads as rewritten:50"§ 15A-974. Exclusion or suppression of unlawfully obtained evidence.			
 c. Articles (other than food) intended to affect the structure or any function of the body of man or other animals; andanimals. d. Articles intended for use as a component of any article specified in paragraphs a, b or c; but does not include devices or their components, parts, or accessories. (8) The term "food" means all of the following: a. Articles used for food or drink for man or other animals, except for cannabis or cannabis-infused products, as defined in G.S. 90-113.112, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. b. Chewing gum, andgum. c. Articles used for components of any such article. " SECTION 4.5.(a) G.S. 15A-974 reads as rewritten: "§ 15A-974. Exclusion or suppression of unlawfully obtained evidence. 			
 function of the body of man or other animals; andanimals. Articles intended for use as a component of any article specified in paragraphs a, b or c; but does not include devices or their components, parts, or accessories. (8) The term "food" means all of the following: a. Articles used for food or drink for man or other animals, except for cannabis or cannabis-infused products, as defined in G.S. 90-113.112, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. b. Chewing gum, andgum. c. Articles used for components of any such article. " SECTION 4.5.(a) G.S. 15A-974 reads as rewritten: "§ 15A-974. Exclusion or suppression of unlawfully obtained evidence. 			•
 d. Articles intended for use as a component of any article specified in paragraphs a, b or c; but does not include devices or their components, parts, or accessories. (8) The term "food" means all of the following: a. Articles used for food or drink for man or other animals, except for cannabis or cannabis-infused products, as defined in G.S. 90-113.112, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. b. Chewing gum, andgum. c. Articles used for components of any such article. " SECTION 4.5.(a) G.S. 15A-974 reads as rewritten: "§ 15A-974. Exclusion or suppression of unlawfully obtained evidence. 			
 paragraphs a, b or c; but does not include devices or their components, parts, or accessories. (8) The term "food" means all of the following: Articles used for food or drink for man or other animals, except for cannabis or cannabis-infused products, as defined in G.S. 90-113.112, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. Chewing gum, andgum. Chewing gum, andgum. SECTION 4.5.(a) G.S. 15A-974 reads as rewritten: "§ 15A-974. Exclusion or suppression of unlawfully obtained evidence. 			•
 39 parts, or accessories. 40 41 (8) The term "food" means all of the following: 42 a. Articles used for food or drink for man or other animals, except for 43 cannabis or cannabis-infused products, as defined in G.S. 90-113.112, 44 that are manufactured by a production facility or sold by a medical 45 cannabis center, as defined in G.S. 90-113.112. 46 b. Chewing gum, andgum. 47 c. Articles used for components of any such article. 48" 49 SECTION 4.5.(a) G.S. 15A-974 reads as rewritten: 50 "§ 15A-974. Exclusion or suppression of unlawfully obtained evidence. 			1 7 1
 40 41 (8) The term "food" means all of the following: 42 a. Articles used for food or drink for man or other animals, except for 43 cannabis or cannabis-infused products, as defined in G.S. 90-113.112, 44 that are manufactured by a production facility or sold by a medical 45 cannabis center, as defined in G.S. 90-113.112. 46 b. Chewing gum, andgum. 47 c. Articles used for components of any such article. 48" 49 SECTION 4.5.(a) G.S. 15A-974 reads as rewritten: 50 "§ 15A-974. Exclusion or suppression of unlawfully obtained evidence. 			
 41 (8) The term "food" means all of the following: 42 a. Articles used for food or drink for man or other animals, except for 43 cannabis or cannabis-infused products, as defined in G.S. 90-113.112, 44 that are manufactured by a production facility or sold by a medical 45 cannabis center, as defined in G.S. 90-113.112. 46 b. Chewing gum, andgum. 47 c. Articles used for components of any such article. 48" 49 SECTION 4.5.(a) G.S. 15A-974 reads as rewritten: 50 "\$ 15A-974. Exclusion or suppression of unlawfully obtained evidence. 			1 /
 a. Articles used for food or drink for man or other animals, except for cannabis or cannabis-infused products, as defined in G.S. 90-113.112, that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. b. Chewing gum, andgum. c. Articles used for components of any such article. m." SECTION 4.5.(a) G.S. 15A-974 reads as rewritten: "§ 15A-974. Exclusion or suppression of unlawfully obtained evidence. 		(8)	The term "food" means all of the following:
 43 cannabis or cannabis-infused products, as defined in G.S. 90-113.112, 44 that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. 46 b. Chewing gum, andgum. 47 c. Articles used for components of any such article. 48" 49 SECTION 4.5.(a) G.S. 15A-974 reads as rewritten: 50 "\$ 15A-974. Exclusion or suppression of unlawfully obtained evidence. 		~ /	
 that are manufactured by a production facility or sold by a medical cannabis center, as defined in G.S. 90-113.112. b. Chewing gum, andgum. c. Articles used for components of any such article. " SECTION 4.5.(a) G.S. 15A-974 reads as rewritten: "§ 15A-974. Exclusion or suppression of unlawfully obtained evidence. 			•
 45 <u>cannabis center, as defined in G.S. 90-113.112.</u> 46 b. Chewing <u>gum, andgum.</u> 47 c. Articles used for components of any such article. 48" 49 SECTION 4.5.(a) G.S. 15A-974 reads as rewritten: 50 "§ 15A-974. Exclusion or suppression of unlawfully obtained evidence. 			
 b. Chewing gum, andgum. c. Articles used for components of any such article. 48" 49 SECTION 4.5.(a) G.S. 15A-974 reads as rewritten: 50 "§ 15A-974. Exclusion or suppression of unlawfully obtained evidence. 			
 47 c. Articles used for components of any such article. 48" 49 SECTION 4.5.(a) G.S. 15A-974 reads as rewritten: 50 "§ 15A-974. Exclusion or suppression of unlawfully obtained evidence. 			
 48" 49 SECTION 4.5.(a) G.S. 15A-974 reads as rewritten: 50 "§ 15A-974. Exclusion or suppression of unlawfully obtained evidence. 			
 49 SECTION 4.5.(a) G.S. 15A-974 reads as rewritten: 50 "§ 15A-974. Exclusion or suppression of unlawfully obtained evidence. 		"	1 2
50 "§ 15A-974. Exclusion or suppression of unlawfully obtained evidence.			ION 4.5.(a) G.S. 15A-974 reads as rewritten:
	51		·

General Assem	bly Of North Carolina Session 202
(1)	Its exclusion is required by the Constitution of the United States or the
	Constitution of the State of North Carolina; or
(2)	It is obtained as a result of a substantial violation of the provisions of this Chapter. In determining whether a violation is substantial, the court mus consider all the circumstances, including:
	a. The importance of the particular interest violated;b. The extent of the deviation from lawful conduct;
	c. The extent to which the violation was willful;
	d. The extent to which exclusion will tend to deter future violations o
	this Chapter.
	Evidence shall not be suppressed under this subdivision if the person
	committing the violation of the provision or provisions under this Chapte
	acted under the objectively reasonable, good faith belief that the actions were
	lawful.
	idence was obtained as the result of a search that was supported by probable
	of the search, no evidence obtained as a result of that search shall be suppressed
•	sis of either of the following:
<u>(1)</u>	A subsequent determination that a substance believed to be a controlled
	substance at the time of the search was not a controlled substance.
<u>(2)</u>	A subsequent determination that the presence of a controlled substance at the
	time of the search was not a violation of law.
	court, in making a determination whether or not evidence shall be suppressed
	n, shall make findings of fact and conclusions of law which shall be included in
_	ant to G.S. 15A-977(f)."
	TION 4.5.(b) This section becomes effective December 1, 2021, and applies to
	or after that date.
	TION 5. G.S. 90-87(16) reads as rewritten:
"(16)	5 I I E
	growing or not; the seeds thereof; the resin extracted from any part of such
	plant; and every compound, manufacture, salt, derivative, mixture, o
	preparation of such plant, its seeds or resin, but shall not include the mature
	stalks of such plant, fiber produced from such stalks, oil, or cake made from
	the seeds of such plant, any other compound, manufacture, salt, derivative
	mixture, or preparation of such mature stalks (except the resin extracted
	therefrom), fiber, oil, or cake, or the sterilized seed of such plant which is
	incapable of germination. The term does not include industrial hemp as
	defined in G.S. 106-568.51, when the industrial hemp is produced and used in
	compliance with rules issued by the North Carolina Industrial Hemp
	Commission. The term does not include an adequate supply as defined in
	G.S. 90-113.112 of cannabis for medical use in compliance with Article 5H
SE A	of Chapter 90 of the General Statutes."
	TION 6. This act is effective when it becomes law and applies to acts committee
on and after that	uate.